SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG)
REPORT 2025
Contents ABOUT THIS REPORT
MESSAGE FROM THE CHAIRMAN
GOVERNANCE
OF PRODUCTS AND SERVICES
Corporate Governance 10 Product Quality and Safety 25
ABOUT SNIBE 03 Corporate governance structure 10 Quality management system 25
Safeguarding shareholders' rights and interests 13 Product quality and safety management 29
SNIBE IN 2025 04
Milestones 04 ESG Governance 14 Focusing on R&D and Innovation 33
Key Performance 06 ESG governance structure 14 Ever-improving R&D and innovation system 33
Honors and Recognitions 08 Communication with stakeholders 14 R&D and innovation capability 35
Assessment of important issues 16 R&D and innovation results 39
Intellectual property protection 47
Compliance in Operation 20
Risk management and control 20 Supply Chain Management 48
Probity and self-discipline 20 Supplier management 48
Information security 22 Supplier communication 49
Sustainable supply chain management 50
Responsible Marketing 51
PROMOTING GREEN OPERATION 58 Responsible marketing management 51
Responsible brand building 52
Environmental and Occupational Health 59 Responsible marketing training 55
and Safety Management
Customer Service Quality 56
Addressing Climate Change 62 Customer service management and capabilities 56
Customer satisfaction 57
Green Operation 64 Improving customer service capabilities 57
Emissions and waste management 65
Resource and energy management 65
Attraction and Retention of Talents
Industry Exchange and Cooperation
Diversity and equal employment 68 Industry-University-Research collaboration and 82
Employee rights and benefits 70 multi-center research
Employee care and communication 72 Academic extension 84
Driving industry standardization 86
Employee Training and Development 73 International exchanges and cooperation 89
Training system 73
Employee ability improvement 74 Community Commonweal 90
Employee promotion and development 76 Support for research and education 90
Supporting community commonweal 92
Occupational Health and Safety 78
Occupational health 78
Safety management 79
Key Performance Indicator Table 93
Appendix 98
ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025 ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025
ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN
The year 2025 marks the conclusion of the 14th Five-
Year Plan, and the in vitro diagnostics (IVD) industry faces
multiple challenges, including the deepening of centralized
procurement, cyclical adjustments, and supply chain
restructuring. As an enterprise with the mission of "creating
value for human health", we firmly believe that the value of an
Overview > This is the fifth environmental, social, and governance (ESG) report issued by Shenzhen enterprise lies in upholding its original aspirations, persisting
New Industries Biomedical Engineering Co., Ltd. According to the principles of objectivity, in innovation, and bravely assuming its responsibilities in the
standardization, transparency, and comprehensiveness, this report discloses detailed information face of adversity. This year, we have been working diligently
concerning the Company's practice and performance in the field of sustainable development in on standardized governance, independent innovation, green
a new chapter for Chinese IVD enterprises amidst industry
fluctuations.
Scope of This report is an annual report and covers relevant data from Jan. 1, 2025 to Dec. 31, 2025. As some
Reporting > of the data in this report involve continuity and comparability, some contents are appropriately
We have solidified the foundation for development
extended or traced as needed. through standardized governance. We firmly believe
that standardized governance is the cornerstone for an
This report covers Shenzhen New Industries Biomedical Engineering Co., Ltd. and its subsidiaries. enterprise to achieve steady and long-term development. In
line with the implementation of the new "Company Law of
Standards for This report is mainly prepared with reference to the "Global Reporting Initiative (GRI) Standards", the People's Republic of China", we have comprehensively
Reporting > "Shenzhen Stock Exchange Self-Regulation Guidelines for Listed Companies No. 17 - Sustainable revised the "Articles of Association" and several governance
Development Report (Trial)", "Shenzhen Stock Exchange ChiNext Self-Regulation Guidelines for systems, added an employee representative director, and
Listed Companies No. 3 - Sustainable Development Report Preparation", and the United Nations further optimized the governance structure of the board.
Facing the normalization of centralized procurement,
"Guide for Business Action on the Sustainable Development Goals (SDGs)", in order to continuously
we have carried out rigorous audit supervision and anti-
improve the transparency of the disclosure of sustainable development reports and respond to the
commercial bribery efforts, not only strictly controlling intelligent solutions.
information needs of stakeholders.
marketing compliance but also improving operational
efficiency through lean management. We place great We strictly control the quality lifeline and safeguard
Explanation > For better elaboration and understanding, "Shenzhen New Industries Biomedical Engineering Co., importance on investor relations and, during this period of the well-being of patients with a sense of
Ltd." is also referred to as "Snibe", "We", or "the Company" in this report. industry valuation reshaping, strive to convey the long-term responsibility. In the context of medical insurance cost
value of the Company's sound operations to the market, control and centralized procurement price reduction,
The monetary amounts in this report are measured in RMB unless otherwise specified. effectively protecting the rights and interests of shareholders, we have always upheld the enterprise spirit of "Quality
especially small and medium-sized investors. is our life". We further strengthen the full lifecycle
Confirmation and This report was approved for release at the 7th Meeting of the 5th Board of Directors of the quality management system and continuously
We adhere to innovation-driven development and define the enhance the traceability and risk prevention and
Approval> Company on Apr. 27, 2026. The Company and all members of the Board of Directors warrant that
industry's standards through technological breakthroughs. control capabilities of the supply chain. What we
the contents disclosed in this report are true, accurate, and complete, and that there are no false
Amidst increasingly homogenized competition in the industry, pursue is not only the accuracy of test results, but also
records, misleading statements, or major omissions.
we focus on our strengths, such as chemiluminescence, to help reduce misdiagnosis rates and unnecessary
and continuously push the limits of single-machine speed medical expenses through technological innovation,
Access to the This report includes paper and electronic versions. You can read and download the electronic measurement and detection accuracy. We continue to make so that every reagent and every instrument carries
Report and version of this report on Juchao Information Network (www.cninfo.com.cn), the designated breakthroughs in small molecule detection, rare diseases, the warmth of alleviating the burden of diagnosis and
Feedback > information disclosure website of the Shenzhen Stock Exchange, or the official website of Snibe and the research and development of geriatric, pediatric, treatment for patients.
(www.snibe.com), and obtain more company information. If you have any questions or suggestions and maternal products, allowing innovative achievements
about this report, please send an email to Snibeinfo@snibe.cn or call +86-755-86540062. to benefit a wider population. At the same time, we keenly We promote green operation and respond to the
embrace the wave of "artificial intelligence + healthcare". By challenges of our time with low-carbon practices.
This report is prepared in Chinese. The English version is the translation of the Chinese version. empowering R&D with digitalization, we have significantly With increasing attention to sustainable development
If there is any ambiguity in the understanding of the English version, the Chinese version shall improved both R&D efficiency and success rates. Our both domestically and internationally, we continue
independently developed fully automated sample processing our efforts in energy conservation, emission reduction,
prevail.
system, SATLARS T8, prioritizes emergency cases and and resource recycling, and continuously enhance the
features intelligent scheduling throughout the entire sample efficiency of energy and resource utilization through
testing process, greatly shortening sample turnaround time technological, equipment, and method improvements.
and helping laboratories improve quality and efficiency with We actively respond to China's carbon peaking and
ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025 ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025
carbon neutrality strategy, systematically promote greenhouse gas accounting and management, and take concrete actions
to respond to the call for global climate change governance. SNIBE IN 2025 The kick-off meeting of "Multi-center Research on
We empower our employees to grow and unite organizational strength through diversity and inclusion. We always regard the Clinical Application of High-sensitivity Troponin I
Concentration and Changes in the Assessment of Acute
talent as our most valuable core asset. We deepen the concept of diverse and equal employment, improve the training system
Milestones > Myocardial Infarction" was successfully held
and promotion channels, establish a perfect salary and benefit system and incentive mechanism, provide a comfortable
working environment and diverse welfare, and take various welfare and care measures to create a highly sticky environment Cardiovascular disease is the "number one killer" that threatens
for talents, enhance employees' sense of belonging and achievement, and promote the common growth of employees and The multi-center clinical study on primary aldosteronism human health, seriously endangering national health. Early
the Company. was concluded, contributing to the screening and diagnosis and precise treatment are the keys to saving lives.
treatment of hypertension This meeting focused on in-depth discussions on the precise
We fulfill social responsibility and give back to society's expectations with professional expertise. As a national enterprise, diagnosis and treatment of myocardial infarction and the
The "Conclusion Meeting of the Series of Studies on Diagnostic application of high-sensitivity troponin in emergency triage,
leveraging our professional advantages, we actively promote the allocation of high-quality medical resources to grassroots
Markers of Primary Aldosteronism and Seminar on the Current injecting new momentum into the prevention and control of
levels. Through strategic partnerships with leading healthcare institutions, we drive translational research to enable early
Status, Challenges, and Countermeasures of Primary Aldosteronism cardiovascular diseases.
diagnosis and treatment of chronic diseases and support medical education and talent cultivation. In the grand vision Diagnosis and Treatment", sponsored by the Laboratory and
for global healthcare, we are committed to serving global health needs with intelligent manufacturing from China and Clinical Branch of the Chinese Society of Cardiothoracic and
contributing Chinese strength to building a healthier, fairer, and more sustainable future. Vascular Anesthesiology, co-organized by the Chinese Endocrine
Hypertension Collaborative Group, and organized by the Company,
Sustainable development is an enduring journey. Guided by unwavering reverence for human life and health, we harness was grandly held in Shenzhen. The conclusion of this multi-center
innovation to address evolving healthcare imperatives and uphold our corporate mission through responsible stewardship. research on primary aldosteronism screening has promoted the
Looking ahead, we will continue to drive innovation and take responsibility, forging new paths amidst change and working standardization of primary aldosteronism screening and diagnosis
in China.
hand in hand with every partner to write a brilliant chapter for Chinese IVD enterprises!
Chairman: Rao Wei
Apr. 27, 2026
ABOUT SNIBE
Company Introduction > MAGLUMI X10, a flagship
fully-auto chemiluminescence
Since its founding in 1995, Snibe has focused on the field of IVD and developed itself into a national high-tech enterprise immunoassay analyzer with a Biossays C10, an automatic
The project "Multi-center Research to
specializing in the R&D, production, sales, and services of IVD products. Since its inception, the Company has dedicated itself Establish the Reference Interval for throughput of 1000 T/H, was biochemistry analyzer with a
to the mission of "customer-centric, market-oriented, creating value for human health through continuous innovation" to High-sensitivity Troponin I in Apparent certified for market launch throughput of 2000 T/H, was
provide customers with better IVD products and services. After 30 years of profound development, technology iteration, and Healthy People in China" was successfully certified for market launch
customer accumulation, the Company's products have broken the monopoly and technology blockade of overseas giants on concluded MAGLUMI X10 represents another
China's IVD market, and Snibe has become a leader in China's IVD field and is evolving into a pioneer in the global IVD field. significant breakthrough for Snibe The launch of the Biossays C10
Laboratory testing of cardiovascular disease in the IVD field, demonstrating demonstrates the Company's strong
biomarkers is susceptible to multiple factors, and its leading strength in clinical R&D capabilities in ultra-high-speed
Corporate Culture >
technologies suitable for precise testing are crucial application and technological biochemistry analyzers, marking
for clinical decision-making. This multi-center innovation, while also injecting new another major breakthrough in the
research on reference interval extensively covers momentum and vitality into the field of biochemistry analyzers in
Mission Core values Vision Spirit key factors affecting biomarker testing, including global healthcare industry. China and moving towards a higher
Customer-centric, market- Assume responsibility To be a leader in Quality is our life multiple regions, diverse populations, various level.
oriented, creating value for bravely China's IVD field ethnicities, and different lifestyles. The research
Enjoy challenge persistently findings will open new paths for the prevention,
human health through continuous Pursue excellence passionately To be a pioneer in the
innovation. global IVD field diagnosis, and treatment of cardiovascular diseases
in China, helping laboratory medicine better serve
people's health.
Company's Ownership Structure >
As of the end of the reporting period, the actual controller of Snibe is Mr. Weng Xianding, whose direct shareholding ratio is
second largest shareholder is Rao Wei, the chairman and general manager of the Company, with a shareholding ratio of
referred to as: Sequoia Juye), with a shareholding ratio of 10.62% (as of the disclosure date of this report, the shareholding
ratio of Sequoia Juye is 8.78%).
ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025 ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025
Hemolumi H6, a high-speed automated The Company won the 2025 China Industry-University- Key Performance >
coagulation analyzer, and Biossays E6 Plus, Research Institute Collaboration Association Science and
a high-speed fully-auto electrolyte analyzer, Technology Innovation Award
were certified for market launch
The Company, in collaboration with top institutions such as Fuwai
The launch of Hemolumi H6 and Biossays E6 Hospital of the Chinese Academy of Medical Sciences, Peking
Economic performance
Plus marks another milestone for the Company University People's Hospital, Fuwai Shenzhen Hospital of the
in the IVD field, providing core laboratories with Chinese Academy of Medical Sciences, and the Second Affiliated
more comprehensive solutions through modular Hospital of Hainan Medical University, jointly conducted the project
integration into total laboratory automation systems. "Small Molecule 'Sandwich Method' Ushers in a New Era of Precise Net profit attributable to
Earnings per share
Diagnosis for Primary Aldosteronism". With its groundbreaking Business revenue shareholders of listed companies
technological innovation and significant industry demonstration
value, it won the third prize of the Innovation Achievement Award. Million Million
RMB RMB/share
RMB
Corporate governance
Proportion of employees Proportion of employees
Investor exchange Information disclosure receiving anti-commercial signing anti-commercial
assessment result bribery training bribery commitments
Nearly
activities
The Company's key reagent
material and process R&D
Several small molecule "sandwich" Snibe R&D and Production team was awarded the title of
assay reagents were certified for Building officially commenced "Guangdong Provincial Advanced
Collective" Quality of products and services
market launch construction
By the end of 2025, the Company's small The Company's key reagent material
The Company's Snibe R&D Building
and process R&D team was awarded the R&D investment Number of valid Number of globally available Quality management
molecule "sandwich" assay reagents have (also known as Snibe Phase V Project)
patents granted chemiluminescence system certificates
title of "Guangdong Provincial Advanced amount
obtained a total of 15 product registration officially commenced construction in
Collective" for its outstanding innovative immunoreagents
certificates. The detection technology is Dec. 2025. Upon completion, the project
becoming increasingly mature, and the strength and social contribution,
will further enhance the Company's Million
service users have expanded from China demonstrating the Company's strength
R&D and innovation capability and RMB
to the world. It is widely used in more in tackling core technologies.
production scale, injecting new
than 100 countries and regions around momentum into the Company's global
the world, helping to achieve precision development.
diagnosis and treatment and contributing
to global healthcare.
Overall satisfaction Total number of confirmed Number of events resulting Number of
with customer complaints received related to in fines or penalties for recalled products
complaint handling infringement of customer privacy breach of regulations
ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025 ABOUT THIS REPORT MESSAGE FROM THE CHAIRMAN ABOUT SNIBE SNIBE IN 2025
Honors and Recognitions >
Attraction and retention of talents
Honor and recognition Issuing authority
Number of employees Proportion of female Proportion of females in Proportion of females in National High-tech Enterprise Science, Technology, and Innovation Commission of Shenzhen
employees management senior management Municipality, Finance Bureau of Shenzhen Municipality, and
Shenzhen Tax Service, State Taxation Administration
National Enterprise Technology Center National Development and Reform Commission
Master Enterprise of "Industry-Education-Assessment" Human Resources and Social Security Department of Guangdong
Skills Ecological Chain in Guangdong Province Province
Listed in the "White List" of Shenzhen Entry-Exit Biomedical Development and Reform Commission of Shenzhen Municipality
Proportion of employees Proportion of employees Total training duration Social insurance coverage
with bachelor degree or covered by year-end Special Products Pilot Enterprises (Institutions) in 2025
above performance appraisal
Top 500 Enterprises in Guangdong Province in 2025 Guangdong Provincial Enterprise Confederation and Guangdong
hours
Provincial Association of Entrepreneurs
Guangdong Provincial Advanced Collective (Key CPC Guangdong Provincial Committee and People's Government
Reagent Material and Process R&D Team) of Guangdong Province
Forbes Asia's Best Under A Billion 2025 List Forbes
China's Top 20 Most Competitive Pharmaceutical Listed HEALTHCARE EXECUTIVE Magazine
Companies in 2025
Environmental and occupational health and safety
Shenzhen's Fourth Batch of Industry-Education Development and Reform Commission of Shenzhen Municipality
Integration Enterprises and Shenzhen Education Bureau
Energy consumption Carbon emission Water intake intensity Volume of reject water
Shenzhen Top 10 Model Platforms for Lifelong Human Resources and Social Security Bureau of Shenzhen
intensity intensity recovered
Vocational Skills Training Municipality
Pingshan District Science Popularization Education Base Science and Technology Innovation Bureau of Shenzhen
tons of CO2 3 Pingshan District
tons of standard m /10,000 RMB cubic meters
coals/10,000 RMB equivalent/10,000 RMB
Grade A in information disclosure appraisal (four Shenzhen Stock Exchange
Coverage of occupational Number of employee deaths due Investment in environmental and consecutive years)
health examination to work-related injuries occupational health and safety
Award
million yuan
The 19th China ESG Top 100 Listed Companies Securities Times
Scored BBB in MSCI ESG Rating MSCI
Scored AA in Wind ESG Rating Wind Information Co., Ltd.
Scored AA in CNI ESG Rating Shenzhen Securities Information Co., Ltd.
Scored AAA in Sino-Securities Index ESG Rating Sino-Securities Index Information Service (Shanghai) Co., Ltd.
Top 100 A-Share Listed Companies in ESG Performance 2025 Sino-Securities Index Information Service (Shanghai) Co., Ltd.
Top 20 A-Share Listed Companies in ESG Performance in Sino-Securities Index Information Service (Shanghai) Co., Ltd.
Pharmaceutical and Healthcare Industry 2025
Corporate Governance ESG Governance Compliance in Operation
Corporate Governance
Corporate governance structure >
REGULATING CORPORATE
The Company, in strict accordance with the "Company Law of the People's Republic of China", the "Securities Law of the People's
Republic of China", the "Code of Corporate Governance for Listed Companies in China", the "Rules Governing the Listing of
GOVERNANCE
Shares on the ChiNext of Shenzhen Stock Exchange", and other relevant laws, regulations, normative documents, and relevant
requirements of China Securities Regulatory Commission, and in consideration of the actual situations of the Company, has
established a corporate governance structure consisting of a board of shareholders, a board of directors, and a management
Major issues team, and formulated and improved the "Articles of Association" and other internal control rules and working procedures to
· Corporate governance guarantee the standardized operation of the corporate governance structure.
· Investor relations
· Compliance in operation In addition, the Board of Directors of the Company has set up four special committees: the Strategy Committee, the Nomination
· Sustainable development management Committee, the Remuneration and Assessment Committee, and the Audit Committee, and formulated corresponding working
· Communication with stakeholders rules, which formed a relatively scientific and standardized governance system and effectively ensured the standardized
· Information security and privacy protection operation and sustainable development of the Company. Among them, the Audit Committee, as the core supervisory body
· Anti-commercial bribery and anti-corruption under the Board of Directors, assumed the functions of the former Board of Supervisors during the reporting period in
· Anti-unfair competition accordance with the provisions of the new "Company Law of the People's Republic of China", further strengthening the internal
supervision mechanism and the Company's governance structure, simplifying the decision-making process, and improving
governance efficiency.
Alignment with Sustainable Development Goals (SDGs)
Board of
Shareholders
Secretary of the Board Board of Special Committees of the
of Directors Directors Board of Directors
Board Office
Strategy Nomination
Committee Committee
General Manager's General Audit Remuneration and
Snibe has always regarded robust and standardized corporate Office Manager Committee Assessment Committee
governance as the foundation of sustainable development.
We continuously improve the governance framework, enhance Anti-Bribery Compliance Internal Audit
Leading Group Department
sustainable development management, deeply integrate the concept
of sustainable development into daily operations, and actively
communicate with stakeholders to respond accurately to the concerns
of all parties. We continue to strengthen compliance management,
Figure - Corporate governance structure
build a comprehensive internal control system, and conduct business
in an honest and self-disciplined manner, providing a solid guarantee
for the steady and long-term development of the Company.
Corporate Governance ESG Governance Compliance in Operation Corporate Governance ESG Governance Compliance in Operation
Convening of three meetings Composition of the Board of Directors and executive team
The Company convenes and holds shareholders' meetings in a standardized manner in strict accordance with the "Rules
for the Shareholders' Meetings of Listed Companies", the "Articles of Association", the "Rules of Procedure for Shareholders'
Meetings", and other regulations and requirements, adopts the combination of on-site voting and online voting, counts the Directors of Non- Independent Female Proportion of Proportion of female
votes of small and medium investors separately when considering major matters affecting the interests of small and medium the Board of independent director directors independent directors directors
Directors director
investors, and discloses the voting results of small and medium investors in a timely manner to ensure that all shareholders,
especially small and medium shareholders, enjoy equal status and are able to fully exercise their rights.
The Board of Directors is responsible to the Board of Shareholders, and the Company convenes and holds the meeting of the
Board of Directors in strict accordance with the relevant provisions of the "Articles of Association" and the "Rules of Procedure
for the Board of Directors". Independent directors are independent of the actual controllers, controlling shareholders, and
other related parties of the Company, and are able to make judgments and express opinions independently to effectively Executives Female executives Proportion of female executives
safeguard the interests of all shareholders, especially small and medium shareholders. The directors of the Company,
through continuous study, familiarization, and mastery of relevant laws and regulations, are committed to safeguarding the
best interests of the Company and all shareholders, and perform their duties in a faithful, honest, and diligent manner.
Three meetings held by the Company in 2025 were counted as follows:
Basic information about the Board of Directors and executive team
Board of Shareholders Meetings of the Meetings of special committees Meetings of
Twice 3 7 3
Board of Directors of the Board of Directors Independent Directors Expertise Remuneration
Name Position Gender Age
Industry Risk man- Accou- Law composition
Marketing
times times times experience agement nting
Rao Wei Chairman and general Male 61 √ Basic salary + annual
manager performance bonus
Weng Heming Non-independent director Male 28 √ Not on the Company's
payroll
Rao Jie Non-independent director Female 37 √ √ Basic salary + annual
Diversification of the Board of Directors and executive team performance bonus
Li Xu Non-independent director Male 51 Not on the Company's
The Company's Board of Directors consists of 8 directors, including 3 independent directors, 1 employee representative
√
director, and 3 female directors. Members of the Board of Directors are highly experienced in fields such as biomedicine, payroll
Wu Qianhui Independent director Female 53 Fixed allowance for
financial audit, risk control, and law, respectively.
√
independent directors
Shen Weihua Independent director Female 55 Fixed allowance for
The executive team of the Company consists of 6 executives, including 4 female executives. The team consists of professionals
√ √
in biomedicine, finance, marketing, clinical testing, etc. With a wealth of management experience, the team is able to independent directors
capitalize on market opportunities and put into action effectively. The general manager and other executives are appointed Zhi Yi Independent director Male 46 √ Fixed allowance for
or dismissed by the Board of Directors. The general manager presides over the production and operation management of the independent directors
Company, organizes the implementation of the resolutions of the Board of Directors, and reports to the Board of Directors. He Xin Employee representative Male 29 √ Basic salary + annual
director performance bonus
The Company strictly abides by the "Code of Corporate Governance for Listed Companies" and has formulated the Ding Chenliu Deputy general manager, Female 50 √ Basic salary + annual
"Remuneration Management System for Directors and Senior Management" to establish a scientific and reasonable chief financial officer performance bonus
remuneration structure and achieve a balance between incentives and constraints. The Remuneration and Assessment Li Tinghua Deputy general manager Female 48 √ Basic salary + annual
Committee of the Board of Directors is responsible for drafting the remuneration plan and assessment standards for performance bonus
the Company's directors and executives, reviewing the performance of directors and executives and conducting annual Liu Haiyan Deputy general manager Female 46 √ √ Basic salary + annual
assessments of them, and supervising the implementation of the remuneration of directors and executives in accordance performance bonus
with the "Working Rules of the Remuneration and Assessment Committee of the Board of Directors". The remuneration plan Zhang Lei Deputy general manager, Female 43 √ √ Basic salary + annual
secretary of the Board of performance bonus
Directors
for directors is decided by the Board of Shareholders, and the remuneration plan for executives is approved by the Board
of Directors, explained to the Board of Shareholders, and fully disclosed. The basic salary of the Company's executives is
Yuan Jinyun Deputy general manager Male 39 √ √ Basic salary + annual
performance bonus
determined based on their positions within the company, job responsibility level, and ability level. The annual performance
bonus is directly linked to the Company's operating performance, with the assessment based on the Company's annual
operating goals and the individual's annual performance evaluation indicators.
Corporate Governance ESG Governance Compliance in Operation Corporate Governance ESG Governance Compliance in Operation
Safeguarding shareholders' rights and interests > ESG Governance
Information disclosure
Guided by investor needs and based on compliance, Snibe attaches great importance to information disclosure, discloses
relevant information in a truthful, accurate, timely, fair, and complete manner in strict accordance with relevant laws and
regulations, as well as the requirements of the "Articles of Association", the "Information Disclosure Management System", etc.,
and actively fulfills its information disclosure obligations, and the Company designates "China Securities Journal", "Securities
Times", "Shanghai Securities News", and "Securities Daily" as information disclosure newspapers and Juchao Information
Network (www.cninfo.com.cn) as the website for information disclosure, so as to ensure that the vast number of investors can
obtain accurate information on an equal basis and in a timely manner. ESG governance structure >
In 2025, Snibe issued 95 announcements, including 4 periodic reports and 91 temporary announcements. In the 2024-2025 A robust ESG management mechanism is pivotal for the top-down implementation of the company's sustainability strategy.
annual information disclosure appraisal for listed companies on the Shenzhen Stock Exchange, Snibe was awarded the According to relevant laws and regulations and the sustainable development governance requirements of listed companies,
highest grade of "A (Excellent)" for the fourth consecutive year, reflecting a high level of recognition of Snibe's information Snibe continues to refine its ESG governance framework and optimize internal sustainable management.
disclosure by the regulatory authorities and the capital market.
The Board of Directors serves as the supreme decision-making body for Snibe's ESG governance, and is responsible for leading
Investor relations and supervising the Company's ESG initiatives, and reviewing and approving ESG-related planning, targets, and policies.
Snibe attaches great importance to communication with investors and strictly follows relevant laws and regulations as Subordinate to the Board, the Strategy Committee is tasked with deliberating on ESG-related topics,reporting periodically to the
well as the "Company's Investor Relations Management System". The chairman is responsible for leading investor relations Board on ESG performance, providing guidance and recommendations for ESG implementation, andmonitoring the execution
management affairs, the secretary of the Board of Directors is the person in charge of investor relations management affairs, of improvement plans.
and the Office of the Board of Directors is the functional department of the Company's investor relations management. In
addition, we continue to learn from excellent investor relations management experience, constantly try to carry out investor Under the Strategy Committee, there are the ESG Work Leading Group and the ESG Work Implementation Group. The ESG
relations management in a more effective way, and ensure that all shareholders have equal access to information by opening Work Leading Group, composed of the general manager and deputy general manager of the Company, drives and monitors
up diverse communication channels. the implementation of ESG programs whileproviding decision-support inputs to the Strategy Committee. The ESG Work
Implementation Group is led by the Office of the Board of Directors, and the heads of various departments and subsidiaries
In 2025, we issued 12 record sheets of investor relations activities, conducted regular briefings on performance reporting, serve as team members and designated liaisons. This cross-functional team cooperates with various departments and
reverse roadshows, and broker strategy meetings, and organized nearly 300 investor exchange activities of various types. subsidiaries of the Company to implement ESG-related work, and summarize the progress and performance of ESG-related
With the outstanding comprehensive strength and stable profitability, we won the "Most Valuable Investment Award" at the work.
Communication with stakeholders >
Snibe always values and maintains effective communication with stakeholders. We fully consider the impact of our own
operations on all stakeholders, understand the opinions, suggestions, and expectations of stakeholders by establishing a
regular communication mechanism, and actively respond to the concerns of stakeholders, which serve as the basis for the
Company's fulfillment of its responsibility for sustainable development.
Stakeholder Issue of concern Form and manifestation of communication
Government and Addressing Climate Change Comply with national laws and regulations
regulatory agencies Compliance in Operation Improve the compliance management system
Anti-commercial bribery and anti-corruption Establish an anti-commercial bribery system
Product safety and quality Strictly control the product quality
Industry exchange and cooperation Create cooperation programs and platforms
Community commonweal Actively participate in government projects
Respond to government policies
Carry out charitable projects
Corporate Governance ESG Governance Compliance in Operation Corporate Governance ESG Governance Compliance in Operation
Stakeholder Issue of concern Form and manifestation of communication
Assessment of important issues >
Shareholders and Corporate governance Improve the corporate governance system Snibe attaches great importance to and continuously improves the identification, management and analysis of important
investors Sustainable development management Improve the compliance management system issues, and takes the concerns of various stakeholders as an important consideration in formulating sustainable development
Compliance in Operation Enhance risk management and control strategies, so as to accurately and effectively respond to the issues of interest to stakeholders, thereby providing an important
Investor relations Fulfill the obligation of information disclosure reference for identifying and managing risks and opportunities.
Product R&D and innovation Organize and participate in investor exchanges
Product safety and quality Increase efforts in R&D and innovation This year, we invited stakeholders to participate in the survey in the form of an online questionnaire to understand their key
Intellectual property protection Strengthen intellectual property management concerns, covering all employees, customers, suppliers and partners, shareholders and analysts, media, industry associations,
governmental organizations, non-governmental organizations, etc. Guided by the "Double Materiality" principle, that is,
"Financial Materiality" and "Impact Materiality", we systematically evaluated and prioritized these issues.
Customers Product safety and quality Strictly control the product quality
Product R&D and innovation Increase efforts in R&D and innovation
Information security and privacy protection Enhance customer privacy management Steps for assessing important issues
Responsible Marketing Maintain compliance in marketing
Anti-unfair competition Strictly abide by business ethics
Customer Service Quality Improve the service quality Results analysis and
Conduct customer satisfaction survey Issue identification and update Issue survey issue ranking
Suppliers and Product Quality and Safety Strictly control the product quality With reference to the "Shenzhen Following the "Double By comprehensively
partners Chain Management Strengthen supplier quality management Stock Exchange Self-Regulation Materiality" principle, we considering the results of
Anti-commercial bribery and anti-corruption Organize supplier meetings and training Guidelines for Listed Companies invited stakeholders to peer benchmarking and
Equal treatment of SMEs Establish an anti-commercial bribery system No. 17 - Sustainable Development conduct a questionnaire stakeholder survey, the issues
Intellectual property protection Strengthen intellectual property management Report (Trial)" (hereinafter referred to survey on the assessment of were assessed and analyzed
as the "Guidelines"), GRI Standards "Financial Materiality" and from two dimensions: the
Employees Diversity and equal employment Organize employee care activities and other international standards, "Impact Materiality". importance to the economy,
Employee rights and benefits Establish communication channels for employees SDGs, and outstanding practices in society, and environment,
Employee training and development Employees' Congress and Labor Union the industry, and in combination and the importance to the
Occupational Health and Safety Provide diverse training programs with the Company's business growth Company's finance, and
Develop a transparent promotion policy and ESG practices, we identified the issues were ranked by
Improve the employee salary management and other important issues on the 21 importance.
performance management system topics specified in the "Guidelines"
Establish the environmental and occupational of Shenzhen Stock Exchange
health and safety system and formed a list of topics after
comprehensive evaluation.
Industry associations Product R&D and innovation Actively carry out industry exchanges
and professional Industry exchange and cooperation Create cooperation programs and platforms
organizations Provide practice and research bases
Community and Product safety and quality Strictly control the product quality
media Emissions and waste management Strictly control waste discharges
Industry exchange and cooperation Create cooperation programs and platforms
Community commonweal Carry out charitable activities
Biodiversity conservation Participate in volunteer service
Maintain good communication with the media
Corporate Governance ESG Governance Compliance in Operation Corporate Governance ESG Governance Compliance in Operation
Matrix of importance issues For the seven issues with high financial materiality, we further identified the associated risks and opportunities and assessed
the potential impact of these risks and opportunities on the Company's strategy, decision-making, financial condition,
operating results, cash flow, and other factors in the short term (1-3 years), medium term (3-5 years), and long term (more
Impact Materiality
than 5 years). In addition, for each issue, the corresponding sections of this report will systematically disclose the Company's
Responsible Marketing Product safety and quality
Occupational health and safety Product R&D and innovation measures in monitoring, prevention, management, control, and mitigation of the impact.
Information security and privacy Intellectual property protection
protection Compliance in operation
Anti-commercial bribery and anti-
corruption
Customer Service Quality
Financial Risks and impacts Opportunities and Impact Section of
materiality impacts time management
issues horizon measures
High
Product safety If product safety and quality Establishing a full lifecycle Short Product
Industry exchange and cooperation Sustainable development management Employee rights and benefits and quality management fails to consistently quality management system term Quality and
Environmental management Supply Chain Management meet regulatory requirements or is that is stricter than regulatory Medium Safety
Corporate governance inadequate, it may lead to product requirements, strengthening term
Anti-unfair competition recalls, regulatory penalties, and product competitiveness Long
Medium
Investor relations damage to brand reputation, resulting through rigorous quality control term
Communication with stakeholders in customer loss and a decline in and quality management
Employee Training and Development market share. systems, and enhancing brand
Emissions and waste management
value and driving business
expansion by high-quality
products and services.
Resource management
Energy management Product R&D The IVD industry is characterized by Conducting forward-looking Short Focusing
Diversity and equal employment and innovation rapid technological iteration. If the planning, focusing on clinical term on R&D and
Low
Equal treatment of SMEs
innovation direction is disconnected needs, developing innovative Medium Innovation
Community commonweal
Biodiversity conservation
from market demand, R&D investment solutions, building technical term
Addressing Climate Change will fail to generate expected returns, barriers, exploring new Long
resulting in sunk costs, missing markets through differentiated term
opportunities in emerging markets, competition, and creating new
lagging product line iteration, revenue growth drivers.
falling into homogeneous low-price
competition, and ultimately leading to
a decline in profitability.
Low Medium High Financial Materiality
Intellectual Negligence in intellectual property Establishing a sound intellectual Medium Focusing
property management and patent portfolio may property management system term on R&D and
protection lead to infringement and imitation of and patent portfolio, building Long Innovation
core technologies, which will weaken technical barriers, protecting term
Environmental category Social category Governance category market pricing power and competitive core technologies from
moats. infringement, and developing
Addressing Climate Change Product R&D and innovation Corporate governance new profit channels through
Emissions and waste management Product safety and quality Compliance in operation patent licensing and technical
Energy management Intellectual property protection Sustainable development management cooperation.
Resource management Supply Chain Management Communication with stakeholders
Environmental management Customer Service Quality Investor relations
Compliance in Against the backdrop of increasingly Building a sound compliance Short Compliance in
operation stringent global regulations in the IVD management system, term Operation
Biodiversity conservation Responsible Marketing Anti-commercial bribery and anti-corruption
industry, any non-compliance may controlling compliance-related Medium
Information security and privacy protection Anti-unfair competition
lead to financial losses, and serious risks, and maintaining excellent term
Diversity and equal employment
violations may result in the business compliance records will help Long
Occupational health and safety being ordered to suspend operations tap into high-end overseas term
Employee Training and Development for rectification, thereby undermining markets, enhance customer
Employee rights and benefits the foundation of an enterprise's trust, highlight management
Industry exchange and cooperation operation. advantages during industry
Equal treatment of SMEs reshuffling, and thereby secure
Community commonweal a stable market share.
Corporate Governance ESG Governance Compliance in Operation Corporate Governance ESG Governance Compliance in Operation
Financial
materiality
Risks and impacts Opportunities and
impacts
Impact
time
Section of
management
Compliance in Operation
issues horizon measures
Anti- The IVD industry involves hospital Establishing a sound anti- Short Compliance in
commercial procurement and distributor bribery management system, term Operation
bribery and management, making it a highly promoting a culture of Medium
anti-corruption sensitive field for corruption. integrity and compliance, term Risk management and control >
Commercial bribery and corruption and continuously improving Long
incidents may bring significant and optimizing internal term We have established an internal oversight system in accordance with the relevant national laws and regulations and the
economic costs and legal management systems and "Notice on Strengthening the Internal Control Construction of Listed Companies and Proposed Listed Enterprises and Promoting
consequences to a company. processes can effectively reduce Internal Control Evaluation and Audit", the "Basic Standards for Internal Control of Enterprises" promulgated by the Ministry of
the risk of corruption. At the Finance, and the "Guidelines for Internal Control of Listed Companies" issued by Shenzhen Stock Exchange, and continuously
same time, an integrity and optimized the "Manual for Internal Control Management" and the "Internal Audit Management System", providing guidance for
compliance brand image can internal audit supervision.
lower marketing and market
entry costs. The Company has established a sound internal control and risk management framework. The Audit Committee is set up
under the Board of Directors, which is responsible for the supervision, inspection, and evaluation of the Company's internal
Customer End customers in the IVD industry Leveraging digital services, Short Customer control, financial information, and internal audit. Under the leadership of the Board of Directors and the Audit Committee of
service quality require continuous services such as responding to technical support term Service Quality the Board of Directors, the Company has established the Internal Audit Department, which is responsible for formulating and
instrument maintenance, technical promptly, enhancing customer Medium improving internal audit, internal control, and other internal management systems, performing comprehensive risk assessment
support, and result interpretation. stickiness and satisfaction, term and monitoring of various business processes, independently conducting internal audit and routine audit of all business
Slow after-sales service response or establishing a customer Long departments and subsidiaries of the Company every year, forming audit reports and rectification proposals on the risk matters
inadequate technical support will feedback mechanism, driving term identified through the audits, continuously following up the implementation of rectification proposals, assisting the audited
lead to a decline in end customer innovation and optimizing departments or subsidiaries in improving relevant business systems and risk management processes, strengthening the risk
satisfaction, directly cause equipment service experience, continuously management capabilities of the departments, and effectively reducing the risks in the Company's operation.
suspension and declining reagent consolidating customer
sales, and ultimately affect the relations, and providing support To further enhance the collaborative efficiency of risk management, the Internal Audit Department has gradually achieved deep
sustainability of the main business. for the long-term development integration of legal affairs, compliance, and internal control. By breaking down functional barriers and promoting information
of the business through high- sharing and data integration, the accuracy of risk identification has been significantly improved. The legal function ensures the
quality services. legality and compliance of all business activities through contract review, legal consultation, and dispute resolution, thereby
preventing legal risks at source. The internal audit function identifies operational risks through audit projects and supervises
Employee The IVD industry is highly dependent Building a diverse and inclusive Short Attraction and the implementation of corrective measures to ensure that the Company's operations comply with internal and external
rights and on the technology accumulation of work environment, providing term Retention of regulations. The coordinated operation of these two functions comprehensively enhances the overall risk management and
benefits R&D personnel and the professional a competitive remuneration Medium Talents control level of the Company.
promotion capability of marketing and incentives system, career term
personnel. A lack of a competitive development opportunities, and Long In 2025, the Internal Audit Department focused on three core pillars: marketing, supply chain, and corporate functions, and
remuneration system and career health and safety safeguards, term conducted comprehensive and in-depth audits by assigning dedicated auditors to focus on each pillar. This year, we completed
development channels, or the existence and establishing a strong audits of 8 offices in China, visits to 156 distributors, contract process management audits of 11 core functional departments,
of employment risks, may lead to the employer brand can attract visits and bidding for 36 projects, and final account audits for 32 projects. From offices to distributors and from contract
loss of core talent, affect product R&D high-quality talent in the processes to project settlements, the Internal Audit Department is committed to promoting efficient resource allocation and
progress and market stability, and industry, stimulate innovation continuous process optimization through independent supervision and evaluation functions, thus safeguarding the Company's
increase management difficulty and and motivation, and improve sustainable development.
operational costs. per capita productivity.
Probity and self-discipline >
Snibe strictly abides by laws and regulations such as the "Anti-Unfair Competition Law of the People's Republic of China", the
"Criminal Law of the People's Republic of China", and the "Interim Provisions on Prohibition of Commercial Bribery", adheres to
the management concept of "compliance first", bases on the development strategy of "steady operation", and implements the
compliance culture of fairness, integrity, and "Do things right". We hold a "zero tolerance" attitude towards any form of bribery,
and strictly prohibit any form of bribery in public or private during the course of business. In 2025, no cases of fraud were found
Corporate Governance ESG Governance Compliance in Operation Corporate Governance ESG Governance Compliance in Operation
in the Company's internal audits, and no internal or external reports of corruption were received. Supervision and improvement
According to the "Control Procedure for Internal Audit", "Control Procedure for Corrective Action and Preventive Action", and
Anti-bribery compliance management other system and procedure documents, the Anti-Bribery Compliance Team has conducted continuous monitoring of the
The Company has established a comprehensive anti-bribery compliance management system. We have disclosed the "Snibe effectiveness of the design and implementation of the anti-bribery management system, and self-rectified the defects and
deficiencies. On the one hand, the Internal Audit Department will regularly conduct internal anti-bribery compliance audits
Anti-Bribery Compliance Policy" on the Company's official website to clarify the Company's overall objectives, policies, and
according to the annual plan to identify system defects and deficiencies and urge the implementation of rectification. On
requirements for anti-bribery compliance management. We have set up an Anti-Bribery Compliance Leading Group, and
the other hand, we will continuously optimize the system based on the improvement recommendations identified during the
formulated and implemented the "Anti-Bribery Compliance Management Handbook" as well as a series of compliance
annual external surveillance audits to ensure the effectiveness of the system.
management norms and control procedures to ensure the effective operation of the anti-bribery management system.
The anti-bribery compliance team, composed of Internal Audit Department and internal auditors of various departments, The Company's official website publicly discloses the hotline, email address, and mailing address for reporting issues to
undertakes anti-bribery compliance functions. ensure that external stakeholders can conveniently and safely report problems. Physical complaint mailboxes without
surveillance coverage have been set up in public areas within the Company's headquarters campus to effectively protect the
Since successfully passing the ISO 37001 anti-bribery management system certification audit, the system has been operating privacy of whistleblowers and encourage internal employees to exercise oversight in accordance with regulations. In addition
smoothly. We have closely monitored external regulatory developments, promptly collected information, and systematically to passively receiving reports, the Internal Audit Department, in conjunction with the General Manager's Office, is responsible
optimized the system control procedures based on the latest anti-bribery policies and guidelines. To further enhance the for accepting on-site reports. Meanwhile, the Internal Audit Department proactively collects feedback and complaints from
operational efficiency of the system and strengthen the ability of various departments to identify and respond to bribery risks, the end of the business chain by conducting on-site visits to distributors and suppliers every year, extending oversight to the
front line of cooperation. For potential non-compliance identified through reported clues or audit findings, the Internal Audit
we comprehensively revised the "Control Procedures for Bribery Risks" and "List of Bribery Risks" during the reporting period,
Department will conduct investigations according to relevant procedures and requirements, and make suggestions on whether
making them more closely aligned with actual business scenarios and significantly enhancing their practical guidance, thus
to take disciplinary measures based on the investigation results.
laying a solid foundation for building a more resilient compliance defense line.
Build a corruption-free environment Reporting channels
In order to enhance the anti-bribery compliance awareness and ability of employees, we regularly conduct on-site anti-bribery
compliance training for all employees, and provide special training to new employees, management, compliance team, ● Official website of the Company: https://www.snibe.com/(Supervision and Reporting Module)
personnel in important positions such as marketing, finance, procurement, and HR, as well as external business partners. ● Address: Internal Audit Department, Snibe Building, No. 23 Jinxiu East Road, Jinsha Community, Kengzi
We regularly provide employees with publicity of anti-bribery laws and regulations, cases, and the Company's anti-bribery Street, Pingshan District, Shenzhen 518122
● Email: audit@snibe.cn
policies through the Company's official website, internal mails, OA system, etc. As mandated by the "Employee Handbook",
● Tel.: +86-755-26706462
all employees are required to sign the "Letter of Commitment for Anti-Bribery Compliance" upon onboarding. Additionally,
business partners must sign the "Letter of Commitment for Business Ethics", "Anti-Commercial Bribery Agreement" or other
equivalent anti-corruption documentation prior to commencing collaboration with the Company. Information security >
We advocate that our business partners join hands with us to maintain sufficient anti-bribery compliance communication and Snibe strictly abides by the "Data Security Law of the People's Republic of China", the "Cybersecurity Law of the People's
sharing, to jointly build an honest, transparent, and incorruptible anti-bribery compliant environment, and to share the value Republic of China", the "Administrative Measures for the Graded Protection of Information Security" and other national laws,
created by compliant operation. regulations and industry norms, fully assumes the responsibilities for information security entities, and continuously deepens
the construction of information security systems. In 2025, the Company reported no information security incidents and no
In 2025, we conducted 14 anti-commercial bribery trainings for internal employees and business partners, and 100% of leakage of customer, employee, and business partner information.
employees have received the anti-commercial bribery training and signed anti-commercial bribery commitments.
Information security management
The Company attaches great importance to information security management, continuously deepens the construction of
With the growth of overseas business, during the reporting period, we organized targeted compliance training on
information security management system, and strengthens its own risk management and control capabilities. We have kept
international anti-bribery, sanctions, and export controls in the healthcare industry for the Company's directors, executives, improving internal management measures such as the "Snibe Information Security Management Policy" and the "Snibe
and key personnel in charge of overseas marketing to enhance their compliance awareness and risk prevention capability in Communication Security Management Specification" and further standardized the information security management system
conducting overseas operations. and management processes. In 2025, we initiated the formulation of relevant regulations for the security management of
business systems and servers to standardize the security management of application systems throughout their full lifecycle.
This year, the Company maintained the effectiveness of the ISO 27001 information security management system and
successfully passed the annual external audit. The Company's remote service system Snibe Link retained the certification of
"Level III of National Information Security Level Protection" while continuously expanding its information security compliance
coverage.
Information security management mode
Cybersecurity Committee Executive entity External entity
Executives and relevant responsible IT Department Suppliers, etc.
persons of the Company
Corporate Governance ESG Governance Compliance in Operation
Control and preventive measures
Through the combination of institutionalized management and normalized inspection, the Company has improved its
information security protection capabilities.
In terms of proactive management, the Company applies technical means such as data loss prevention (DLP) system and ESM
storage medium management module to secure data. Through situation awareness testing, we conduct security monitoring
on all servers and user traffic, achieving 100% handling of abnormal alarms. By conducting system penetration testing
and bastion host audits, we preemptively identify and mitigate potential cyber threats. We strictly implement a full-server
vulnerability scan and repair mechanism every six months to ensure timely closure of system vulnerabilities. Additionally, we
have established a sensitive information retrieval mechanism for public cloud drives to proactively investigate unauthorized
storage activities and prevent data leakage risks at source. Following the comprehensive upgrade of the 360 Terminal Security
System, we have achieved automatic daily updates of the virus database and forced distribution to terminals, ensuring that
all employees' terminals are in the latest protection state and effectively improving the overall security baseline. Internal
employees access the wireless network through domain account authentication, and visitors access the wireless network
through SMS verification code authentication to ensure secure wireless network access.
STRICTLY CONTROLLING THE QUALITY
In terms of reactive management, the Company comprehensively upgrades the terminal protection software, implements
the network access authentication mechanism, introduces the anti-tampering backup system, and optimizes the network OF PRODUCTS AND SERVICES
partition access control policy to build a multi-layered and three-dimensional security and protection system. In terms of the
handling of emergency incidents, the Company has developed an information security emergency response plan to clearly Major issues
define the response mechanism, handling process, and measures in case of emergency incidents. · Product safety and quality
· Product R&D and innovation
Furthermore, the Company placesparamount importance on information security awareness initiatives,prioritizes employee · Intellectual property protection
security awareness enhancement as a critical component of its cybersecurity strategy, and has carried out multi-dimensional · Supply chain management
and multi-tiered security training programs. We not only organize information security training for new employees to instill · Responsible marketing
proper information security practices from day one, but also carry out special information security training for all employees · Customer service quality
every year. · Equal treatment of SMEs
Alignment with Sustainable Development Goals (SDGs)
Information security training
In 2025, the Company continued to prioritize cultivating employees' information security awareness and
comprehensively improve the digital security literacy of all employees. We adopted a blended teaching
model combining offline in-person training with online live streaming and interaction, and systematically
organized a special campaign to raise awareness of information security. The training content closely
addressed the security pain points in real-world
work scenarios, and carefully designed practical
course modules including phishing email
identification techniques, key points of personal
information protection, and demonstrations of
common attack methods. The event saw broad
participation from employees, significantly
enhancing their overall security awareness and
prevention capability. It effectively improved "Quality is our life" is the consistent corporate spirit of Snibe. Guided
employees' ability to identify and handle by this belief, we continuously optimize the quality management
information security threats, laying a solid system, increase R&D investment and equipment upgrades, and
foundation for the Company to build a digital constantly improve product quality and supply chain security. Through
security defense line. persistent product and technical reformation, we provide clinicians
with more accurate and reliable testing solutions, continuously
creating value for human health.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Product Quality and Safety
Snibe has long held the spirit of "Quality is our life".
Driven by the spirit, Snibe continues to optimize the
quality management system, increase investment in R&D
personnel and equipment, and enhance product quality
and supply chain safety. Snibe aims to provide more
accurate and reliable testing products for clinical doctors
and create value for human health through continuous
innovation.
Process Relation Diagram of the Quality Management System of the Company
External
Quality management system > Documents Quality
Manual Quality Management
Snibe has established the policy of "Quality is our life" and set strict quality objectives. Besides a systematic, documented, (Policy & Objective) System Guidelines
and well-developed quality management system, an organizational structure with defined responsibilities has been in
place to clarify control requirements for the quality management process. Snibe has also continued to optimize and improve
the quality management system, gaining recognition of its product quality management capability from stakeholders and Procedural documents
ensuring stable product quality and safety amidst rapid business development. Describe the operating
procedures of each process
Quality Assurance Department, Key Reagent Material QC Department, Material Inspection Department, Reagent QC
Department, Instrument QC Department, and Component Inspection Department have been set up to ensure product quality
Quality documents & technical documents
throughout the lifecycle. While strictly abiding by external policies such as the "Quality Management System Requirements", (including systems, regulations,
"Medical Devices - Quality Management Systems - Requirements for Regulatory Purposes", and "Good Manufacturing Practice Describe the specific
specifications, and DMR)
operation of each element
for Medical Devices", Snibe has formulated and implemented such internal management systems as the "Quality Manual" and
"Control Procedure for Product Monitoring and Measurement" that encompass the quality management process, specifications
for products, and equipment use to realize quality manufacturing. Quality record
(including DHR'S, QSR) Quality Management
System operational
evidence
Quality Management System Documentation Structure
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
To align with the Company's global expansion, we enhanced our Quality Management System (QMS) by fully integrating multi-
regulatory compliance requirements, building on the foundation of MDSAP regulatory alignment. This initiative culminated in
the development of a comprehensive "Quality Internal Audit Compliance Manual", which standardized internal audit protocols Regular updates and dissemination of regulations
and ensured systematic and efficient internal audits.
In 2025, the Company conducted 9 regulation
With the expansion of the Company's IVD new product line business, in order to ensure effective quality control of the newly knowledge sharing sessions based on regular
added product line, the Company obtained ISO 9001 and ISO 13485 system certificates for coagulation products during the regulation update tracking, focusing on key
reporting period. regulatory documents in the industry and carrying
out targeted dissemination of information, such
as the List of In Vitro Diagnostic Reagents Exempt
Quality management system certification obtained: from Clinical Trials (2025) and the Guidelines
for Registration Review of Fully Automated
ISO 9001 ISO 13485 MDSAP
Chemiluminescence Immunoassay Analyzers
(2025 revision). These efforts ensured that relevant
personnel could keep abreast of the latest
regulatory requirements and accurately identify
Quality Management System Medical Device Quality Management Medical Device Single Audit the potential impact of regulatory updates on the
Certification System Certification Program Certification Company's quality management system, providing
strong support for the compliance maintenance
and continuous improvement of the system.
Internal audit of quality management system
The effective operation of the quality management system is not possible without a well-developed internal quality
management team. Snibe has set up internal audit groups according to the "Control Procedure for Internal Audit", and
appointed qualified group members. Internal auditors receive expertise and skill training on quality management system
standards and regulations, and internal audit skills and methods. Moreover, they are assessed to ensure that each can
accurately pinpoint and identify nonconformities or defects in the system.
The Company conducts annual internal audits covering the entire product line to ensure compliance with ISO 9001, ISO
Training on the control of operational documents in the quality
management system
implemented and maintained, and continuously improved.
Improved quality management capabilities In 2025, the company conducted a total of 29
To improve the knowledge reserve of personnel in the Quality Assurance Department, a total of 55 training sessions and training sessions related to document control,
learning activities were completed throughout the year, totaling over 12,000 hours, focusing on IVD supervision and including comprehensive document control
upper-level laws and regulations (such as unannounced inspection, supervision, and penalties), facility and equipment training, training on key points of software
management, R&D processes, risk management, hazardous chemical handling, product registration, and post-market document review, and specialized training on key
surveillance. Through systematic learning and practice, the professional knowledge and skill levels of department personnel points of process document review. The training
were effectively improved, providing solid technical support and assurance for the operation of the Company's quality comprehensively enhanced the awareness and
management system. professional ability of personnel in document
suitability and standardization, contributing to the
To strengthen the Company's quality management capabilities and promote the strict implementation of the relevant continuous improvement of the Company's quality
requirements of the quality management system, in 2025, the Quality Assurance Department conducted a total of 110 training management system.
sessions on quality management, covering various aspects such as medical device regulations, document control, design
changes, hazardous chemicals management, equipment management, risk management, and post-market surveillance. The
trainees included relevant personnel of R&D, production, inspection, marketing, quality management, and other departments.
Through the above training sessions, the expertise, skill proficiency, compliance awareness, and risk prevention ability of
relevant personnel have been improved, providing a solid quality management team for the Company's development.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Effective operation and continuous optimization of quality management system In overseas markets, 120 products demonstrated exceptional performance in the
Snibe conducts comprehensive and independent evaluation through supervision and review by external auditors, and EQA programs conducted by leading international accreditation bodies in 2025,
continues to optimize the quality management system based on the assessment and on-site inspection results. including Bio-Rad EQAS, RIQAS, RCPA-QAP, CAP, RfB, UK NEQAS, DEQAS, IFCC, and
NGSP, which also validated the reliability of the Company's products.
In 2025, the Company underwent 13 quality management system audits from government regulatory agencies such as the In 2025, Snibe participated in the 25 Hydroxyvitamin D (25-OH Vit D) DEQAS
Guangdong Medical Products Administration and the Shenzhen Administration for Market Regulation, as well as external and obtained the 2025-2026 Certificate of Proficiency. We also participated in
audit agencies such as T?V, DEKRA, and SGS, including 8 audits by third-party certification agencies, 2 audits on Good the certification programs for glycated hemoglobin by IFCC and NGSP, achieved
Manufacturing Practice for Medical Devices, and 3 audits on the Guidelines for Verification of Quality Management Systems for excellent results, and obtained relevant certificates.
Medical Device Registration, covering the quality management systems of all final product manufacturing sites, achieving a
Through internal and external audits to continuously track the operation of the quality management system, the Company's
quality management system has achieved continuous optimization and quality management capabilities have been
continuously improved, ensuring the high quality output of products.
Product quality and safety management >
External quality assessment
External quality assessment (EQA) is a system for checking, supervising, and verifying the laboratory's performance in order Quality improvement of reference measurement laboratory
to maintain a high standard of practice, and EQA results are largely dictated by the samples provided by the laboratory. To Snibe has built a professional quality management system for the reference measurement laboratory in accordance with
ensure the high-level performance of end users, we encourage EQA participation by domestic and overseas end users, which the international standards of ISO/ IEC 17025 and ISO 15195, passed the review by the China National Accreditation Service
in turn allows us to follow up on product quality, safety, and performance. for Conformity Assessment (CNAS), and obtained the accreditation certificate. Besides, high-end measurement devices
and advanced reference materials at home and abroad have been introduced, and reference methods issued by the
In the domestic market, Snibe participated in 51 EQA programs organized by the National Health Commission in 2025, Joint Committee for Traceability in Laboratory Medicine (JCTLM) and national authorities have been adopted to ensure the
involving 235 items for evaluation, and we have achieved a 100% pass rate in routine EQA for four consecutive years. By the metrological traceability of testing results. We work to build kit testing capacity for the reference measurement laboratory
end of 2025, all the registered chemiluminescence reagent projects approved by the National Health Commission have been and establish a registered internal testing platform in strict accordance with national/industry standards, supporting product
involved in EQA programs. quality inspection.
While playing an active role in the cooperative development of reference methods and the collaborative assignment of
reference materials, Snibe has been a stakeholder member of the Joint Committee for Traceability in Laboratory Medicine
(JCTLM) and a corporate communication member of committees and working groups of the International Federation of Clinical
the Commutability in Metrological Traceability (WG-CMT), driving the standardization and harmonization of related projects.
improve the accuracy and comparability of test results.
By the end of 2025, Snibe has established more than 20 reference measurement procedures for vitamins, therapeutic drug
monitoring, non-peptide hormones, enzymes, etc. Among them, 11 procedures have been approved by the China National
EQA results for the reference measurement laboratory were announced, and Snibe achieved excellent results in 8 IFCC-RELA
programs and 15 NCCL-EQARL programs applied, with a satisfactory pass rate.
In 2025, the Company's reference measurement laboratory passed a routine supervision review by the CNAS regulatory
● National Health Commission EQA Pass Rate ● Domestic Routine EQAS Pass Rate authority.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Improved product quality management capabilities Adverse events and product recalls
In 2025, the Company made a lot of efforts to improve internal quality control, further improving its product quality The Company continuously tracks and monitors the occurrence of post-market adverse events, while closely following updates
management capabilities. At the same time, the Company also promoted a culture of quality management through various and changes in relevant domestic and international post-market regulations and industry standards. On this basis, the
means to enhance employees' quality awareness. Company continuously optimizes and improves processes for post-market adverse event monitoring, recalls, and advisory
notices to comprehensively enhance the effectiveness of post-market supervision.
To guide, organize, and manage adverse event monitoring for medical devices, the general manager is in charge of
The Company standardized the on-site audit management of external suppliers and established
overall control and resource coordination. At the same time, we have set up a steering group that brings together different
on-site audit management regulations and corresponding audit guidelines.
departments, and developed the "Control Procedure for Adverse Event" and supporting procedures and documents to collect
feedback on adverse events from medical institutions, businesses, regulatory authorities, and other relevant parties in a timely
To implement refined management of facilities/equipment/systems, the Company established
manner.
the "Management Regulations for Classification Critical/Facility/Equipment Systems" to
distinguish between critical and non-critical facilities/equipment/systems and redefine the
The Company regularly reports the regulatory situation to the Medical Device Adverse Event Monitoring Working Group. For
revalidation/qualification cycle.
any adverse events that occur, we strictly implement the investigation and evaluation process, conduct in-depth analysis of
potential product risks, and regularly issue periodic risk assessment reports for medical devices. Through data analysis, we
The Company optimized the organizational environment, stakeholder needs, and risk and
actively promote continuous improvement after product launch, achieving continuous monitoring of the full product lifecycle.
opportunity control procedures, and established risk assessment criteria for the quality
management system.
Collect Investigate, Analyze Report Follow-up
& Evaluate
Methods: Report to or Adverse event
● Regulator systems or ● Investigate Adverse event notify the supporting
● Feedback and causes report representatives
To enhance the professional skills of the assembly team, strengthen the awareness of quality and complaints ● Relevance under local
efficiency, promote the spirit of craftsmanship, and facilitate teamwork and experience exchange, the ● Clinical experience evaluation adverse event
Company held the "Craftsmanship for Excellence, Efficiency for Quality" assembly skills competition ● Academic literature ● Risk regulations
in 2025. Through this competition, the Company promoted a quality culture and facilitated the ● Others assessment
implementation of quality culture and awareness.
Response to adverse events
In addition, the Company relies on the after-sales service stations in various regions to ensure a timely response within
Information such as customer hotline, email, and fax is provided on product labels and the official website of the Company to
ensure that customers have sufficient channels to complain and inquire about product problems.
The Company formulated the "Control Procedure for Feedback and Complaint Handling", specifying the critical workflow
milestones in feedback and complaint handling, and the categories of feedback information, so as to guide regional
professional engineers to investigate, analyze, and follow up on feedback and complaints in accordance with the
requirements of the procedure document.
In 2025, 100% of complaints received have been addressed.
The Company formulated the "Control Procedure for Recall of Medical Devices", which was cross-linked with complaints,
adverse events, and post-market supervision. At the same time, we timely analyzed, investigated, and evaluated the collected
Product label and traceability management information to ensure that a recall was readily initiated according to regional laws and regulations.
In accordance with the "Control Procedure for Identification and Traceability", the Company has taken measures to prevent
identification mix-ups and misuse throughout the process of product implementation. We have established a unique device In 2025, Snibe had no product recall and received no regulatory warning or punishment on our product or service quality.
identifier (UDI) for all medical devices we sell to ensure their traceability.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Reagent R&D platform
Snibe takes chemiluminescence immunoassay products as the core business. After nearly 20 years of continuous innovation
and accumulation, we have mastered the core technologies such as antigen-antibody labeling technology, magnetic sphere-
Focusing on R&D and Innovation
antigen/antibody coupling technology, and chemiluminescence reagent preparation technology, and achieved revolutionary
technological breakthroughs in the field of small molecules. The Company has established a complete reagent development
platform, covering immunodiagnostics, biochemical diagnostics, immunochromatography, molecular diagnostics,
coagulation, and other IVD areas.
Guided by GB ∕ T 42061-2022 IDT ISO13485:2016 "Medical Devices - Quality Management Systems - Requirements for
Innovation is our lifeblood and core competitiveness. Regulatory Purposes" and the actual situation of the Company, the Reagent R&D Department has formulated the "Control
Snibe works to improve our R&D capabilities through Procedure for Design and Development" to define requirements for every phase of new product design and development.
continuous R&D process optimization so that we can Additionally, department-specific processes and standards have been developed and continuously optimized for critical
create more innovative quality products, continue to design and development stages, including the commercial demonstration and project initiation planning process for reagent
develop a whole product lineup, and constantly create products, the process finalization and validation protocol for reagent products, the R&D-to-production transition process
for reagent products, and the design change control process for reagent products, to standardize the management of new
value for human health.
product development process.
Given the large number of projects and abundant information in the rapidly-changing IVD reagent market, it is important to
identify key customer needs. We need to do the right thing in the business environment. To better serve the market with precise
provision of necessary products, our reagent R&D team adheres to the strategies of "market-oriented product development"
Ever-improving R&D and innovation system > and "lifecycle business demonstration", and establishes a decision support mechanism for project initiation. In this way, we
can determine whether a project meets market demand and is available for initiation and delivery.
Instrument R&D platform The business demonstration process is shown below:
The Company has built and kept optimizing the product lifecycle management platform in line with its own characteristics.
Through standardization, process, and data-based management, we have improved the reliability, predictability, and
compliance of R&D projects, enabling product development to be more robust and efficient. After years of practice and
iteration, our R&D management platform has become increasingly mature, providing strong support for product innovation,
quality improvement, and market competitiveness, so that the Company can continuously launch high-quality products that
meet customer needs and market expectations.
Intelligent data management Systematic process End-to-end quality
to improve R&D collaboration control to improve project control for product
efficiency execution excellence
We have built an efficient data We have implemented robust Supported by the R&D
management architecture to achieve process controls across critical management platform,
centralized storage, intelligent product lifecycle phases, we can systematically
association, and dynamic updates covering product definition, manage product quality,
throughout the product lifecycle. Our engineering change, and including design verification,
business teams can work together based version management, to engineering change
on the single source of truth to ensure ensure the transparency, tracking, and quality
information integrity and accuracy and standardization, and system compliance, to
reduce redundancy and communication traceability of the processes at ensure that products meet
costs. At the same time, data traceability all stages, effectively reduce industry regulations and
and version management capabilities of development risks, and shorten high standards, and further
the system have been optimized, which the product launch cycle. improve product stability and
allows the efficient reuse of research safety.
and development results and facilitates
knowledge accumulation and innovation
breakthroughs.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
R&D and innovation capability >
After more than 20 years of hard work, Snibe has built a mature R&D system that spans the entire industry chain. There are four In 2025, our R&D investment was a year-on-year increase of accounting for
technology platforms targeting the R&D of magnetic microspheres, key reagent materials, diagnostic reagents, and automatic
diagnostic instruments.
million yuan
of our revenue.
R&D capability enhancement
Over 30 years of technology
Recombinant protein expression ● Improvement of instrument R&D capabilities
accumulation
Magnetic Key reagent Antibody preparation The research and development of IVD instruments is a highly integrated work, covering electronics, mechanical engineering,
Proprietary magnetic microspheres material R&D
microsphere preparation Protein and small molecule software engineering, and many other fields. We are committed to building an industry-leading R&D system, continuously
R&D technical technical
technology modification improving our core competitiveness, and developing more breakthrough IVD instrument products. To this end, we have made
platform platform
One of the few manufacturers Primer and probe synthesis constant efforts to deepen and improve our R&D capabilities in the following five areas.
with such an advanced R&D
platform in the industry
R&D Strengthening We actively foster an open R&D ecosystem by establishing long-term cooperative relations
platform
Reagents for chemiluminescence interdisciplinary with universities and research institutions, driving the application-driven translation of
immunoassay, biochemical cooperation cutting-edge technologies. For example, we set up a postdoctoral innovation practice base
analysis, nucleic acid analysis, and and technology and bring experts from different disciplines into R&D projects. Through interdisciplinary
Microelectronics R&D IVD IVD reagent
instrument R&D coagulation analysis integration collaborative innovation, we continue to expand the boundaries of technology and accelerate
Software R&D
R&D technical Technical CNAS-accredited reference the implementation of new technologies in instrument research and development.
Mechanical design and
platform platform laboratory
manufacturing
Stakeholder Member of the Joint Building a We have established a complete intellectual property management and protection system,
Committee for Traceability in systematic covering patent applications, technical confidentiality, and intellectual property risk
Laboratory Medicine intellectual property management and control. The Company has a dedicated intellectual property management
management team, responsible for the evaluation and protection of technological achievements, to
system ensure that innovative achievements are legally and effectively safeguarded. At the same
time, through regular training and internal publicity, we raise R&D personnel's awareness
of intellectual property and promote the continuous generation of high-value patents and
R&D investment and team building
software copyrights.
Snibe has maintained friendly exchanges and communication with key universities and developed long-term on-campus
recruiting plans to ensure a steady stream of talents. At the same time, Snibe has been recruiting social talents and Stimulating We advocate an innovation-driven development model, and encourage R&D personnel to
independently training R&D professionals and persons in charge. By far, it has built an efficient and high-quality team that innovative thinking keep an open mind and dare to challenge the traditional technology path. The Company
identifies with corporate culture. and cultivating provides sufficient experimental resources and exploration space for the R&D team, supports
exploring spirit cutting-edge technology research and new product concept verification, and encourages
By the end of 2025, we have engaged 781 R&D professionals, accounting for 28.04% of the total number of employees. Among continuous optimization of product design from experiment and iteration to promote
them, 97.57% are aged 40 or below, and 49.68% have a master's or doctor's degree. A young and high-quality R&D team is technological breakthroughs.
contributing to our R&D and innovation.
Improving We have built a multi-level innovation incentive system, including project meritorious
the incentive service award, technology innovation award, patent incentive plan, and promotion incentive
mechanism and mechanism, to fully stimulate the creativity of the R&D team. Meanwhile, the Company
creating a culture of advocates a proactive and scientific R&D culture, and supports technology exploration and
innovation innovation experiments within a reasonable range. Under a strict quality control system, we
empower the R&D team to systematically advance product solutions through data analysis
Educational and experimental verification, and promote technological progress, while ensuring product
Age distribution background safety and reliability.
of R&D distribution of
personnel R&D personnel Increasing R&D We insist on large R&D investment, providing advanced equipment and perfect experimental
investment and conditions for instrument R&D. In 2023, Snibe completed the Phase III construction of R&D
consolidating the Building, creating a better office and experimental environment for the R&D team and further
technical foundation enhancing the overall strength of instrument R&D and industry competitiveness.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
During the reporting period, the Company's instrument R&D team continued to improve the R&D governance system, focusing ● Reagent R&D capability enhancement
on the goals of high-quality development and sustainable innovation. We deeply integrated digital R&D tools, data-driven In 2025, to drive the synergistic improvement of R&D product quality, efficiency, and sustainability, our R&D system, driven
decision-making, and cross-departmental collaboration mechanism into the full product lifecycle management. By combining by processes and systems, established standardized and visualized R&D management systems and a knowledge base
cutting-edge technologies and scientific methodologies, we built an agile, efficient, green, and sustainable innovation center. This system encompasses the full product lifecycle, including key milestones such as project initiation review, design
ecosystem. This transformation further enhanced the technical barriers and quality excellence of our products, helping the acceptance, design and development transfer, and product registration. Through continuous process/system iteration, it
Company maintain its leading position in industry competition. identifies best practices in the product development process and achieves the greatest balance between product quality
and efficiency.
Improving the R&D • We incorporated digital design, virtual validation, and cross-disciplinary review mechanism In terms of R&D personnel cultivation, professional skills training was provided to employees based on the needs of
management and into the R&D project management process and quality control nodes to strengthen the different positions in the R&D department. In 2025, the Reagent R&D Department conducted a total of 213 training sessions,
quality control institutionalization and traceability of the R&D process. including project experience sharing, professional basic knowledge explanation, and the use of professional tools to
system • We established a joint review mechanism covering multiple functional roles such as R&D, help R&D personnel consolidate their theoretical foundation and master core operational skills. For new employees in
testing, process, quality, and after-sales service to improve the governance capability and the Reagent R&D Department, the Company developed a systematic training plan. In 2025, a total of 169 professional
decision-making transparency of complex projects. skills enhancement courses were delivered, providing strong support for the growth of new employees, ensuring talent
• We continued to advance the mechanism for accumulating R&D knowledge assets and availability for the efficient operation and sustainable development of the department, and laying a solid foundation for
systematically managed historical project experience, test data, and improvement records to
the Company's reagent R&D capability enhancement.
support the organization's long-term learning and capability accumulation.
• We integrated the concepts of green design and resource conservation into R&D
● Improvement of R&D capabilities in key reagent materials
management requirements, guiding projects to simultaneously focus on material utilization,
manufacturability, and maintenance convenience during the design stage. Through relentless technological innovation and product development, the Company has achieved groundbreaking
advancements in the field of small molecules. The key reagent material R&D team has established the R&D platform
Digital (I) Digital design and virtual validation for anti-neoepitop antibodies (antibodies that form new epitopes after the complexation of small molecule antigens
empowerment and • In the conceptual design and scheme demonstration stages, 3D modeling and virtual with their specific antibodies). Such breakthrough has accelerated the development of the Company's small molecule
collaborative R&D prototype technology were routinely applied to carry out system-level layout, interference immunization project. The result of small molecule sandwich assay is highly consistent with that of mass spectrometry,
practices checks, and assembly feasibility analysis in advance. which well compensates for the shortcomings of the competition method. The registration of 16 small molecule dual-
• Through an online review platform, multi-disciplinary collaborative reviews were organized antibody sandwich assay reagents, including 25-hydroxyvitamin D, aldosterone, estradiol, progesterone, testosterone,
to achieve visual display and efficient communication of the design scheme. androstenedione, tacrolimus, vitamin B12, folic acid, free triiodothyronine, total triiodothyronine, free thyroxine, total
(II) Simulation analysis and data-driven optimization
thyroxine, reverse triiodothyronine, cyclosporine, and angiotensin I, has been completed.
• A closed loop of simulation analysis and measurement validation was carried out in key
modules to continuously optimize design parameters.
In terms of antibody preparation, the Company has established a single-B cell preparation technology platform to drive the
• Standardized test schemes and closed-loop problem management processes were
established, shifting quality risks forward to the design and validation stages. high-quality development of rabbit monoclonal antibodies and other novel antibodies, thereby further improving reagent
(III) Collaboration between 3D technology and manufacturing performance, significantly shortening the development cycle for primary antibodies in small molecule projects, and
• Assembly simulation and process validation were applied to reduce repeated modifications improving the overall quality of antibody development. At present, the Company has realized the self-production of iron
to prototypes and lower resource consumption. powder, a key component of the magnetic sphere, which helps to control the quality of in-house iron powder and reduce
• During the mass production preparation stage, joint review of R&D and manufacturing was its batch-to-batch variability. Thus, the supply problem of iron powder was solved, the cost of the kit was further reduced,
promoted to improve process maturity. and the market competitiveness and product accessibility were improved. In addition, the Company has kept increasing
(iv) Agile R&D and cross-departmental collaboration investment in personnel and equipment for the research and development of key reagent materials, so as to improve the
• By adopting a phased review and short-cycle iteration model, the pace of problem R&D capabilities of key reagent materials.
identification and resolution was accelerated.
• By incorporating end-user feedback and after-sales experience into R&D improvement
inputs, product reliability and maintainability were continuously optimized.
In 2025, relying on the in-depth practice of the instrument R&D governance mechanism, the Company's instrument R&D
capabilities and quality robustness continued to improve. On the decision-making side, R&D decisions became more data-
driven, and the ability to identify risks at the front end was significantly enhanced; on the execution side, the trend of design
rework and repeated trial production was effectively controlled, and the efficiency of R&D resource utilization was continuously
optimized; on the product side, reliability, manufacturability, and maintainability were continuously improved; in terms of
team collaboration, cross-departmental collaboration became smoother, the pace of project progress and the efficiency of
problem closure were further improved, and the ability to develop digital and complex systems was significantly enhanced.
This series of advancements signifies that the Company's instrument R&D system has acquired high-quality, sustainable
endogenous growth momentum.
Gas Chromatograph Fully Automated Synthesis Workstation
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
R&D and innovation results >
With the original intention of "making medical examinations more affordable for the public", Snibe has pursued independent Biossays C6/Biossays C6P
innovation while developing our core business as a socially responsible employer. We work to create value for human health, Automatic Biochemistry Analyzer
thus making quality medical resources available to all.
Biossays C6/Biossays C6P are mid-to-high-end automatic
Instrument R&D results biochemistry analyzers under development by the Company.
Thanks to enhanced R&D efforts, we have delivered a lineup of instruments with increased accuracy and efficiency, providing The biochemical module has a throughput of 1000T/H. For
reliable data for clinical diagnosis and promoting the accessibility of medical resources. Among them, the SATLARS mini-T8 the electrolyte testing module, Biossays C6 is equipped
Laboratory Automation System and the Biossays C6/Biossays C6P Automatic Biochemistry Analyzer are the company's key with a self-developed direct method electrolyte module
instrument products under development in 2025. These two products aim to reduce the affordability of medical terminals and with a throughput of up to 500T/H, while Biossays C6P is
improve testing efficiency. equipped with an indirect method electrolyte module with
a throughput of up to 600T/H, meeting the requirements of
different terminals.
Both analyzers support direct loading of whole blood
without pretreatment, enabling efficient clinical diagnosis.
Adopting a modular design, they can be interconnected
SATLARS mini-T8
with the MAGLUMI X6 chemiluminescence immunoassay
Laboratory Automation System
analyzer to form a biochemical immunoassay automation
system. They also support connection to a total laboratory
SATLARS mini-T8 is an intelligent assembly line designed for compact spaces in the laboratory department. It highly integrates
automation system, better meeting the needs of large-scale
sample pre- and post-processing functions, enabling unattended automated operation from sample loading to testing,
terminals.
storage, and disposal.
No additional scattered pretreatment or transfer equipment is required, effectively solving the pain points of equipment clutter
and low space utilization in the laboratory department and reducing manual transfer and handover steps by more than 80%.
SATLARS T8
Equipped with AI vision-based serum quality identification and automatic quality control functions, it eliminates problems such
Laboratory Automation System (aliquoter module added)
as sample contamination, missed or erroneous testing, and information entry deviations at source, significantly streamlining
the operation procedures of the department, improving sample turnaround efficiency, and helping the laboratory department
SATLARS T8 is an open automation system developed by Snibe with completely independent intellectual property rights. It
achieve standardized, intelligent, and efficient operations of samples.
fully integrates the five modules of biochemistry, immunoassay, electrolyte, coagulation, and molecule. The whole process of
sample loading, transport, processing, testing, and storage is automated, greatly reducing manual intervention and improving
testing efficiency. The unique two-way four-track design makes sample scheduling more flexible toward dynamic balance.
Modular design and multi-type tracks can be adapted to different laboratory spaces and meet different testing requirements
through flexible configuration. Emergency priority and intelligent scheduling can greatly shorten the TAT of samples. A
specialized data processing and information management system can help departments realize better quality management.
The development of the SATLARS T8 aliquoter module was completed in 2025.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
In 2025, the Company's integrated biochemical and immunoassay analyzer Biolumi CX10 was a finalist in the International Diabetes is a highly prevalent chronic disease worldwide. According to the 2021 report by the International Diabetes
Design Excellence Award (IDEA), and the Company's electrolyte analyzer Biossays E6Plus won the Gold Award at the French Federation, approximately 537 million adults worldwide have diabetes, and this number is projected to rise to 784 million by
Design Award. The two design awards stand as a strong testament to the innovation capabilities of our instrument R&D team 2045. China has the largest number of diabetes patients in the world, with approximately 140 million patients, accounting
and the growing global influence of our brand. These two products are also the first products to receive such awards. for about 26% of the global total. To improve the diagnosis rate of diabetes, the Company developed an anti-zinc transporter
According to the positive rate of glutamic acid decarboxylase antibody (GADA) in the population with newly diagnosed classic
type 1 diabetes mellitus (T1DM) in China, the combined detection of protein tyrosine phosphatase antibody (IA-2A) and Anti-
ZnT8 can increase the positive rate by 10% to 15%. The launch of the Anti-ZnT8 product effectively fills the diagnostic gap,
improves the detection efficiency, promotes the precise subtyping of T1DM, and enables early warning and individualized
treatment decisions.
In the cardiovascular field, Snibe successfully developed the 11-dehydrothromboxane B2 assay kit (magnetic particle based
chemiluminescent immunoassay) based on the small molecule sandwich technology R&D platform. Leveraging the technical
advantages of small molecule sandwich materials and methods, it breaks through the sensitivity limitations of traditional
ELISA, quantifies the degree of platelet activation, accurately identifies patients with biochemical resistance, provides a basis
for intensive intervention in high-risk populations, and guides the adjustment of medication regimens. The kit is also suitable
for primary healthcare institutions, enabling screening and triage of low-risk patients at the grassroots level, thereby freeing
up resources at Grade A tertiary hospitals and implementing tiered diagnosis and treatment. It directly serves the core goal of
the "Healthy China 2030" initiative to reduce the mortality rate of cardiovascular diseases.
Promoting the R&D of geriatric, pediatric, and maternal products
The Company actively responds to the requirements of documents like the national "Healthy China 2030 Planning Outline", the
Reagent R&D results "State Council's Opinions on Implementing Healthy China Initiative", the "14th Five-Year Plan for National Health" and WHO
During the reporting period, the Company completed the registration of 9 new chemiluminescence reagents and 9 new initiatives to promote the research and development of geriatric, pediatric, and maternal diagnostic products.
biochemical reagents, which enriched the Company's reagent type in autoimmune antibodies, liver fibrosis, and infectious
diseases. The global treatment cost for Alzheimer's disease (AD) is projected to reach $1.89 trillion by 2050. Early screening and
diagnosis can slow disease progression, reduce the need for mid-to-late stage care, and help achieve the goal of "healthy
Attention to rare diseases aging". To this end, the Company has carried out the R&D of cerebrospinal fluid and blood detection products related to AD,
Snibe focuses on the study of rare diseases. We actively develop relevant products so that the life and health of patients with helping to comprehensively promote the prevention and control of dementia in the elderly. As of the end of the reporting
rare diseases are guaranteed. In addition to the rare diseases previously disclosed, the rare diseases we are working on during period, the Company had completed the development of multiple AD blood test kits (Aβ1-40, Aβ1-42, p-Tau-181, p-Tau-217,
the reporting period are as follows: etc.), which are of great significance for the prevention and control of AD. First, this technology breaks through the bottleneck
of early identification. Cerebrospinal fluid testing and PET scans are invasive, expensive, and difficult to popularize, while
blood?based neurological biomarker testing, with its high sensitivity and specificity, non-invasiveness, and cost-effectiveness,
has become the key to breaking the deadlock. It also supports large-scale community screening, enabling convenient and
Rare disease Product universal early diagnosis. Second, blood biomarkers allow for dynamic monitoring of disease progression and treatment
efficacy to guide precise intervention, and combined monitoring can quantify pathological progression. Finally, China has
Atypical haemolytic uraemic sC5b-9, soluble terminal complement
the largest number of AD patients in the world (over 11 million patients aged 60 and above), with higher risks in rural areas
syndrome, aHUS complex assay kit (magnetic particle based and among women. This technology can effectively address the challenges of China's aging population and optimize the
chemiluminescent immunoassay) public health prevention and control system. It provides a core tool for building a full-chain system of "screening-diagnosis-
treatment-prevention" for China's aging society, and is of strategic significance for reversing disease progression and
alleviating public health pressure.
In 2024, China's State Council issued the "Several Measures on Accelerating the Improvement of the Fertility Support Policy
Attention to chronic disease management and prevention System and Promoting the Construction of a Fertility-Friendly Society", which would implement in depth the Maternal and
With the increasing aging of population in China, chronic diseases have become a major health threat. Under the value-based Infant Safety Promotion Action Plan and the Birth Defects Prevention and Treatment Capacity Enhancement Program. Human
healthcare framework, to address this dilemma and further optimize chronic disease diagnosis and treatment pathways, parvovirus B19, a pathogen capable of maternal-fetal transmission, may compromise fetal development. In alignment with
we have launched appropriate and precise testing technologies through the innovation and application of cutting-edge national policies, the Company has accelerated the development of human parvovirus B19 antibody detection solutions and
technologies in laboratory medicine, which provides a new direction for chronic disease management guided by value- enhanced its comprehensive and high-quality TORCH screening panels. As of the end of the reporting period, the Human
based healthcare and helps optimize the full lifecycle management of chronic diseases and clinical diagnosis and treatment Parvovirus B19 IgG Antibody Test Kit (magnetic particle based chemiluminescent immunoassay) had obtained the registration
pathways. test report and entered the clinical registration phase.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Facilitating the improvement of global public health services centralized and decentralized testing solutions, the Company assisted medical institutions at different levels in enhancing their
Respiratory tract infections pose a long?term challenge to global public health. Their high transmissibility, pathogen diversity, testing capabilities. The specific activities undertaken are as follows.
and symptom similarity place enormous pressure on clinical diagnosis, treatment, and disease prevention and control.
As a pioneer in the global in vitro diagnostics field, we deeply understand that diagnostic products are not only medical
Incorporating •Incorporate product planning for centralized terminals and primary healthcare settings into the
tools, but also an important component of the public health defense system. In 2025, we conducted R&D of a series of
healthcare annual R&D roadmap, with a focus on supporting regional laboratory capacity building and the
testing products aimed at improving public health services and combating infectious diseases. These included respiratory
accessibility development of the tiered diagnosis and treatment system.
multiplex testing products that detect pathogens such as influenza A, influenza B, respiratory syncytial virus, adenovirus, and goals into •At the new project initiation stage, concurrently assess equipment deployment conditions, staffing
Mycoplasma pneumoniae. The goal is to accurately identify pathogens through a single sampling and testing, especially for R&D strategy levels, operational costs, and long?term maintenance requirements, and treat accessibility and
vulnerable groups such as infants, young children, and the elderly. This provides comprehensive etiological evidence to guide affordability as key decision dimensions.
precise medication, thereby curbing the spread of antibiotic resistance at the source, reducing the burden on the medical •Establish a cross-departmental collaboration mechanism, uniting marketing, after-sales, clinical
system, and safeguarding public health. support, and supply chain teams, to incorporate end-user feedback and public health needs into
product planning inputs.
Facilitating early screening, early diagnosis, and personalized diagnosis and treatment of cancer •Embed energy efficiency, durability, and life?cycle cost management requirements into the R&D
Guided by China's policy of early diagnosis and treatment, the Company actively advances the development of early screening evaluation system, to promote the economic viability and sustainability of products over long?term
operation.
and diagnostic products for cancer, aiming to promote its early screening, early diagnosis and early treatment and to reduce
cancer incidence and mortality rates.
Expanding (I) Product R&D planning for centralized terminals
healthcare The Company is developing two new products for medium?throughput centralized testing terminal
DNA methylation detection, as a rapidly developing molecular detection technology for cancer in recent years, has shown service scenarios, including a medium?speed biochemistry analyzer and an integrated sample processing
promising application prospects in early cancer risk assessment and auxiliary diagnosis. It features non-invasive or minimally coverage system, both soon to be launched:
invasive sampling and the ability to capture potential early signals, making it suitable for risk assessment and clinical through •Both products are designed to enhance the testing capabilities of regional laboratories, optimize
decision support in specific populations. In addition, DNA methylation biomarkers are being explored for disease progression innovative manpower allocation, and improve operational efficiency, meeting centralized testing needs.
assessment and prognostic analysis in some studies and specific application scenarios. design and •The system architecture emphasizes modular design and scalability, enabling medical institutions
platform- to gradually configure equipment based on testing volume, thereby reducing the pressure of one-
The Company has achieved breakthrough progress in the field of methylation?based early cancer screening. Based on based R&D time investment.
methylation-specific PCR technology, the Company has developed single-cancer screening or auxiliary detection products for •By integrating sample pre?processing, automated transmission, and information system integration
functions, manual operations are reduced and process stability is improved.
multiple high-incidence cancers, covering application scenarios such as colorectal cancer and cervical cancer. These products
•During the design phase, attention is also given to deployment space, power conditions, and
are used to detect the methylation of specific genes in the population using various sample types, including fecal samples,
environmental adaptability to enhance applicability across medical institutions in different regions.
human peripheral blood plasma, and cervical exfoliated cells, assisting clinicians in disease diagnosis. Regarding methylation
(II) Optimizing product design to improve usability
instruments, the R&D of methylation instruments had been completed by the end of the reporting period, facilitating early •Continuously improve the user interface and interaction logic to reduce training costs;
screening and early diagnosis of related diseases. •Strengthen intelligent reminders, operation monitoring, and remote support capabilities to improve
the transparency of equipment operation;
Malignancies have become one of the major disease burdens worldwide. The traditional "trial?and?error" approach of •Introduce multi?scenario use validation during the R&D phase to ensure product suitability for
chemotherapy not only delays patient treatment, but also results in enormous waste of medical resources and patient different medical environments.
suffering. As a "navigator" for precision medicine, the core value of companion diagnostics lies in finding the right drug for the (III) Adopting a modular and standardized design to improve affordability
right patient at the right time. To this end, the Company has introduced a digital PCR platform through strategic cooperation, •Promote platform-based architecture and standardization of core components to control R&D and
which, with its high sensitivity and excellent quantification capabilities, provides more precise medication guidance for cancer manufacturing costs;
•Optimize part and component selection and process solutions to enhance supply chain stability;
patients. During the reporting period, relying on this technology platform, the Company achieved key breakthroughs in two
•Adopt a durable design and maintenance-friendly structure to reduce life?cycle operation and
major cancers, breast cancer and non?small cell lung cancer.
maintenance costs.
(IV) Supporting applications in primary and resource?limited regions
By dynamically monitoring drug?resistant mutations using the digital PCR platform, treatment regimens can be adjusted in •Optimize installation and deployment methods to improve operational reliability in complex
a timely manner, supporting personalized diagnosis and treatment and avoiding the huge medical expenditures incurred environments;
by ineffective targeted therapies, as well as the radiation exposure and resource consumption from unnecessary imaging •Promote low?energy?consumption design to reduce operational burden;
examinations. This approach not only respects life but also maximizes the use of limited medical resources. •Fully cover scenarios of continuous operation and simplified maintenance during the validation
phase.
Promoting access to quality medical resources (V) Using digital tools to empower laboratory efficiency
Adhering to the original intention of "making medical examinations more affordable for the public", the Company is •Use data analysis and operational monitoring functions to help laboratories shorten testing
continuously promoting accessibility to high-quality medical resources. In 2025, the Company's Instrument R&D Department turnaround time;
•Strengthen system interconnection capabilities to support laboratory informatization;
consistently prioritized enhancing accessibility to medical services, improving clinical user experience, and reducing total cost
•Upgrade software to extend equipment life?cycle.
of ownership as key directions of R&D governance. The concept of accessible and affordable healthcare was systematically
embedded in the product planning, design, development, and validation phases. Through the coordinated development of
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
By systematically embedding the concept of healthcare accessibility into R&D governance and product development practices,
the Company made positive progress in promoting healthcare coverage in 2025, which also reflects its commitment to social
Green production: Promoting efficient and low?carbon collaborative manufacturing
responsibility.
•Material and process optimization to reduce production energy consumption: Relying on lightweight and
integrated front-end design, the demand for raw materials and processing complexity were directly reduced.
In the future, the Company's R&D department will continue to promote technological innovation and process optimization,
The simplified structure reduced material consumption and energy input during production, while the
and remain committed to creating more high-quality and cost-effective medical devices, further improving the accessibility of
streamlined assembly process also reduced labor hours and energy consumption, thus achieving low-carbon
medical resources, and contributing to the sustainable development of the global medical industry.
manufacturing.
Green R&D
•Supply chain collaboration for full?chain carbon reduction: The reduction in the total number of parts enabled
The Company's instrument R&D team continues to delve into the field of sustainable development, integrating the green
upstream suppliers to consume raw materials more precisely, reducing the production and waste risks of excess
sustainability principle into every detail of products' life-cycle management. From the design iteration of core components
materials; the product's overall weight reduction and structural optimization further lowered fuel consumption
to the optimization of production and assembly, and then to subsequent use and resource recycling, the team consistently
and carbon emissions during logistics and transportation, promoting the green transformation of the full supply
leverages technological innovation to minimize environmental impact. By upholding and upgrading its green development
chain.
concept, the Company provides customers with efficient and environmentally friendly solutions while continuously
strengthening its sense of responsibility in the field of green medical equipment.
•Precise consumable management and control to reduce waste volume: For SATLARS mini?T8's sample
processing unit, the reduction in the number of standard parts such as screws used (reduced by approximately
during production and reduced manufacturing waste; the standardized and intensive design also reduced
resource input for subsequent consumable replacement and maintenance, forming a full?cycle green material
management system.
The Company's SATLARS mini-T8 Laboratory Automation System
embodies green concepts and life-cycle design Green packaging: Practicing sustainable logistics
•Continued application of environmentally friendly materials: In this new product, we still actively promoted the
Green design: Advancing lightweight and intensive design replacement of plastics and wood with paper, and used recyclable paper?based substrates and environmentally
•Structural lightweighting to lower both material and energy consumption: For SATLARS mini-T8's cold friendly cushioning materials, significantly reducing dependence on traditional plastics and wood, and lowering
storage unit, we optimized its structural design through simulation analysis while maintaining the resource consumption and environmental pollution.
structural advantages of SATLARS T8. Under the premise that part strength requirements were met, the
weight was reduced by approximately 36%, effectively reducing material usage and directly lowering •Lightweight packaging design: By optimizing the packaging structure and using high-strength thin materials
carbon emissions during subsequent transportation, thereby extending the green value contributed at the and multi-module combination solutions, the total volume and weight of the packaging were effectively
design phase. reduced, which not only saved storage and transportation space, but also directly reduced energy consumption
and carbon emissions during logistics.
•Storage efficiency upgrades to optimize resource utilization: Through systematic design upgrades,
SATLARS mini?T8's cold storage unit achieved a simultaneous improvement in storage density per unit •Strict adherence to international standards: All packaging materials strictly complied with international
volume and overall energy efficiency ratio, truly realizing the green design goal of "create higher value environmental regulations and recycling standards, ensuring they are recyclable and biodegradable. We
with fewer resources" and indirectly reducing energy consumption during use. are committed to providing customers with green packaging solutions that meet global environmental
requirements, supporting the development of a sustainable supply chain.
•Part integration and simplification to reduce resource consumption at the source: A comprehensive
structural integration and simplification was carried out on SATLARS mini?T8's sample processing
unit. By optimizing wiring, simplifying transmission and support structures, and integrating functional
components, the number of part types was reduced by approximately 14% and the number of parts
by approximately 11%. This simplified material management and resource consumption at the source,
facilitated subsequent maintenance and upgrades, and reduced resource waste caused by product
replacement.
•Snap-fit connection optimization to reduce consumable usage: The innovative snap-fit fixing solution
replaced some traditional connection methods, which not only simplified the assembly process and
improved efficiency, but also significantly reduced the number of small consumables such as screws used,
facilitating subsequent maintenance and recycling, and lowering resource consumption during use and
disposal.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Intellectual property protection >
Snibe strictly abides by and implements national and regional laws, regulations, and standards, such as the "Patent Law of
the People's Republic of China" and "Trademark Law of the People's Republic of China", formulates the "Intellectual Property
Management Procedure", "Patent Management Procedure", "Trademark Management Procedure", "Works Management
Procedure" and other management documents, and continuously improves the construction of intellectual property Supply Chain Management
management system.
We pay attention to intellectual property protection. With a dedicated team of professionals and a mature management
system, we integrate intellectual property creation and protection into our R&D and innovation system to provide strong
support and guarantee for our product R&D and technological innovation. Internally, the Intellectual Property Department
adopts early warning for project research, project initiation, R&D, and product launch to manage risks throughout the
development process and protect our technological innovations. Externally, investment, financing, and technological A stable, safe, and quality supply chain provides an important
cooperation are conducted with an early warning mechanism to reduce potential risks. At the same time, we actively organize guarantee for us to offer high-quality products all the time.
training sessions to help employees understand intellectual property compliance and obligations, and strengthen their Guided by "The Bidding Law of the People's Republic of China"
awareness and professional competence in intellectual property protection. and other relevant laws and regulations, Snibe has developed a
sound supplier management system. In addition to the quality
With the outstanding performance in the creation, application, protection, and management of intellectual property rights,
of products and services, the Company also pays attention
Snibe won the title of "National Intellectual Property Demonstration Enterprise" in 2023 and won the title of "National
High-tech Enterprise" in 2024, fully demonstrating Snibe' exemplary and leading role in the independent control of core to the management of suppliers in terms of business ethics,
technologies and the strategic deployment of intellectual property rights. environmental awareness, occupational health and safety, and
continues to convey the concept of sustainable development to
By the end of 2025, the Company has had 743 patents filed, 426 valid patents granted (including 197 valid invention patents), suppliers to ensure the quality and sustainability of suppliers.
Cumulative number of Number of valid patents Cumulative number of valid Cumulative number of
patents filed granted trademarks registered software copyrights
Supplier management >
Management systems such as the "Bidding Management System", the "Control Procedure for Procurement", the "Anti-Bribery
Including valid invention Control Procedure for Procurement Transactions", and the "Supplier HSF Management Regulations" have been formulated
patents
to systematically supervise and manage supplier development and admission, ordering, performance evaluation, re-
evaluation, qualification management, and supplier elimination, forming closed-loop management to ensure the fair and
effective operation of the procurement supply chain.
We continuously optimize supplier management and, in accordance with relevant system requirements, achieve
comprehensive and high-standard management of our major business partners. We conduct anti-commercial bribery
investigations and annual reviews for our major business partners, with a coverage rate of 100%, to prevent compliance
risks at the source. Mandatory anti-bribery training sessions with competency assessments are organized for suppliers,
accompanied by the signing of "Letter of Commitment for Anti-Commercial Bribery" or "Anti-commercial Bribery Agreement",
internalizing integrity-based cooperation as a common principle for both parties. We have completed the signing
of "Environmental and Occupational Health and Safety Policy Notice" across our partner network and the signing of
"Supply Chain Information Security Agreement" with major suppliers, establishing risk control measures for environment,
occupational health and safety, and information security. In addition, this year we have newly formulated the "Supplier On-
site Audit Management Regulations", which not only standardizes the audit management of external suppliers, but also
proactively urges and guides suppliers to improve their management in areas such as quality management, anti-commercial
bribery, environment, occupational health and safety, and information security.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
In accordance with the "Control Procedure for Procurement", the Company conducts annual requalification audits for both Sustainable supply chain management >
probationary and approved suppliers. Suppliers not up to standards are included on the "List of Unqualified Suppliers"
based on the type of materials they supply. Rectification and guidance support are available to urge and help suppliers To ensure the quality and supply safety of important materials, Snibe divides suppliers into three categories of A, B, and C
improve their management processes and measures, thus ensuring the stability and improvement of the supplier quality, by the importance of supplied materials management to the product. Suppliers are reviewed and evaluated with category-
and eliminating unqualified suppliers. Meanwhile, by establishing supplier management files, we regularly record suppliers' specific indicators and standards based on the types of their materials and the nature of business. Category A suppliers are
qualification changes, cooperation updates, and performance. Based on these records, we periodically review and audit required to establish a sound quality management system and sign a quality assurance agreement.
suppliers, monitoring and strictly assessing whether to retain their cooperation eligibility.
After years of technology accumulation, we have established a well-developed supply chain risk management system. On
In 2025, the Company added 50 new suppliers and removed 4 suppliers due to quality issues. the one hand, we enhance the safety inventory management of core components and include more alternative suppliers.
On the other hand, we join hands with domestic manufacturers to develop and apply for major special projects of Shenzhen
to promote the R&D and substitution of domestic core components. For key components, Snibe and suppliers need to work
closely on all-round material recognition to fully guarantee the safety of materials. For some key materials, Snibe has
formulated Plan B to deal with sudden risks in the supply chain. For materials with a large amount of consumption, we usually
Supplier admission Supplier re-evaluation Supplier elimination purchase them from two or three suppliers at the same time to avoid the situation that the production of products is affected
by the shortage of materials. Amidst the push to replace foreign goods with domestic alternatives in the manufacturing
· Preliminary investigation · Supplier classification · Supplier monitoring industry, Snibe has opted for more domestic materials after verification, consolidating supply chain security. Furthermore, the
· Production and R&D capabilities management · Eliminating abnormal strong R&D team for key reagent materials serves as a solid backbone to guarantee the stable supply of raw materials for our
· Quality assurance ability · Supplier qualification suppliers reagent products. At present, most of the Company's key reagent materials have achieved self-sufficiency, effectively reducing
· Intellectual Property Rights management the risk of limited raw material procurement channels and ensuring the stability of the key reagent material supply.
· Environmental health and safety · Risk management of supplier
· Social responsibility and ethical · Organizational Structure As for supply chain operation and inventory management, the annual demand forecasting is updated on a rolling basis (2 + 3,
standards · Price level short-term + long-term) so that both suppliers and Snibe can maintain dynamic safety inventory for quick response to flexible
· Sample validation · Production Capacity demand. At the same time, based on production needs and procurement plans, we collaborate with suppliers to discuss and
· Enquiry and quotation · Quality assurance ability formulate reasonable inventory quantities and delivery schedules, and continuously update these to ensure smooth supply
· On-site certification and review · Environmental risk chain operations and improve delivery flexibility and response speed.
· Anti-commercial Bribery assessment
Investigation · Anti-commercial Bribery When selecting supply resources, we prioritize suppliers that are geographically close to us and have a relatively complete
Investigation system to ensure flexible delivery and timely, effective communication and audit in quality control, as well as in-depth
communication and careful evaluation during R&D cooperation to guarantee stable supply after delivery.
Supplier communication >
Technical exchange is an important measure to ensure product quality. Whenever quality anomalies are identified during
regular supplier performance reviews, we immediately coordinate with relevant departments and suppliers to jointly discuss By the end of 2025, the proportion of suppliers in and the proportion of suppliers in Hong Kong,
solutions. A regular communication and feedback mechanism has been established around the monthly incoming material the Chinese mainland was Macao, Taiwan, and overseas was
pass rate and on?time delivery rate. For suppliers not up to standards or ranking low in performance, we proactively organize
special meetings to invite them to review their quality performance in person. Through in?depth discussions on quality
standards, we establish mutually agreed control standards, and on this basis, formulate effective corrective and preventive
actions as well as quality improvement measures, thereby further enhancing material quality levels. In 2025, we organized
more than 330 online and offline meetings with suppliers.
In the on-site audit stage before the new supplier was admitted, the Procurement Department would jointly conduct on-
site visits and exchanges with the personnel of relevant upstream and downstream departments such as R&D and quality
inspection. Based on the annual evaluation results of suppliers and the problems found in their daily management process,
we would formulate an annual visit plan or arrange an unannounced audit, timely discuss with suppliers about the quality
and sustainable development issues found in the audit, and discontinue the supply from suppliers to be rectified to mitigate
supply risk. In 2025, we conducted a total of 26 pre-admission and annual on-site audits.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
As required by the "Regulations on the Management of Domestic Distributors", Snibe strictly abides by the "Anti-Unfair
Responsible Marketing
Competition Law of the People's Republic of China" and the "Interim Provisions on Prohibition of Commercial Bribery". For
brand building and market development, we have formulated the "Management System for Domestic Academic Conferences"
to regulate the organization of academic conferences and academic promotion. An internal customer management platform,
which covers five modules of customer management, market management, product management, distributor management,
and database, has been developed to help marketing personnel master information on customer relations, meeting
procedures, product information, and online distributor management. This is how we realize responsible marketing.
Snibe has always put the rights and interests of users first.
Through strong brand building, and the domain-specific In overseas markets, under the framework of the Company's ISO 13485 quality management system, we follow the
expertise competency enhancement of the marketing and "Regulations on the Management of Overseas Distributors", implement the ISO 37001 anti-bribery management system
standard, and require overseas distributors to conduct business as per local laws and regulations. To ensure global regulatory
after-sales service personnel, the Company unswervingly
compliance of post-market products, the Company strictly abides by the regulatory requirements of various countries/
implements responsible marketing, continuously elevates
regions for medical devices, and sets appropriate labels when selling products to ensure that the end users are fully aware
client service capabilities, empowers customers, and fosters of the product information. For example, for distributors in the EU, we adapt our products and business to the latest IVDR
industry exchanges and cooperation to expand the Company's and transitional provisions, for example, adding the information of EU importers and updating compliance declaration. To
leadership in the industry. safeguard the interests of distributors and end users, we proactively communicate with customers and end-user hospitals
regarding products undergoing phase-out or discontinuation, providing advance notification of discontinuation timelines to
establish transition periods for users, while simultaneously offering optimized alternative solutions.
Responsible marketing management > Responsible brand building >
Management systems such as "Control Procedure for Customer-Related Processes", "Regulations on the Management Brand control and supervision
of Domestic Distributors", "Regulations on the Management of Overseas Distributors", "Regulations on the Management During product marketing and promotion, the Marketing Department submits the new products and promotional materials
of Publicity Materials", "Regulations on the Management of Intellectual Property Rights in Advertising and Exhibitions", (including the commissioned design of advertisements) to the Intellectual Property Department for review in strict accordance
"Regulations on the Management of Intellectual Property Rights in Market Sales", and "Anti-Bribery Control Procedure for with the requirements specified in the "Regulations on the Management of Intellectual Property Rights in Advertising and
Distributors' Sales Business" have been established to form a sound marketing management framework to ensure the Exhibitions" and the "Regulations on the Management of Intellectual Property Rights in Market Sales", so as to ensure
protection of customer rights and interests and improve customer satisfaction during the course of business. compliance with the Company's requirements for patent, trademark and copyright protection. At the same time, we require
that the content of promotional materials be truthful and scientific, and must not contradict the content of product labels
In both domestic and overseas markets, we adhere to the five principles of equality and mutual benefit, integrity and legal and instructions. Exaggerated statements are prohibited, and the use of text, names, images, or other similar labels that may
compliance, win-win result and long-term cooperation, daily management with regular evaluation, and zero tolerance for mislead users regarding the intended use, safety, or performance of products is forbidden. Furthermore, all materials sent to
bribery to manage distributors. external parties must undergo strict internal approval.
The Marketing Department is responsible for market supervision and risk control and prevention in the product release
and publicity process. The Company also closely monitors the behaviors that damage our brand building, and clarifies the
Communication with customers responsible departments and measures to deal with violations against our intellectual property rights to maintain Snibe's
brand image.
Brand building
In 2025, the Company launched several major instrument products, including the ultra-high-speed fully-auto
chemiluminescence immunoassay analyzer MAGLUMI X10, the ultra-high-speed biochemistry analyzer Biossays C10, the
high-speed fully-auto electrolyte analyzer Biossays E6 Plus, and the high-speed automated coagulation analyzer Hemolumi
H6. The successive launches of these products provide important opportunities for the Company's brand building. The
Company actively promotes brand building across all departments. We continue to carry out brand promotion through
various channels and forms such as exhibitions, academic conferences, and official WeChat accounts to enhance the
Identification Determination Review of Implementation After-sales
Company's industry influence.
of product of product product of bidding and feedback
requirements requirements requirements contract/order
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
In terms of brand building in overseas markets, the Overseas Sales Department and Overseas Marketing Department have
held academic exchanges such as Snibe Day to enhance the Company's international brand influence.
Promotion of MAGLUMI X10 and Biossays C10
"Snibe Day" is jointly organized by the Company, the International Federation of Clinical Chemistry and Laboratory Medicine
(IFCC), and globally renowned medical associations and laboratories. Focusing on current challenges, future directions,
In Mar. 2025, at the Annual Conference & EXPO, China Congress for Diagnostics & Laboratory Medicine and key issues in medical laboratory immunoassays, the event brings together renowned experts in international medical
(CCDLM) and the 22nd China International In Vitro Diagnostic Expo (CACLP), the Company exhibited laboratory science to share the latest clinical applications and research advances, promoting the translation of research
and launched the fully-auto chemiluminescence immunoassay analyzer MAGLUMI X10 and the next- findings into clinical practice and vigorously facilitating knowledge sharing and cross?border cooperation in the field of in
generation biochemistry analyzer Biossays C10 for the first time in China. MAGLUMI X10, with its ultra?fast vitro diagnostics.
immunoassay throughput of 1000 tests per hour, MPC micro?precision sampling technology, as well as
zero-contamination, zero-pulsation, and zero-degradation steady?state washing technology, ensures In 2025, we successfully held more than 10 "Snibe Day" brand events, which were launched in China and many countries
high efficiency, accuracy, and stability of immunoassays. overseas. The "Snibe Day" events transcend one-way communication. With an open attitude, the Company invited key global
partners to come together, experience the smart production line, and witness how precision instruments were born; they
also visited hospitals to see how the equipment drove efficient diagnosis and treatment. When manufacturing strength meets
clinical needs, we jointly create a closed loop of trust. This is not just a showcase, but a commitment: Snibe ensures that
every technology withstands the test of real-world application.
International Symposium on Laboratory Medicine
On Aug. 24, 2025, the International Symposium on Laboratory Medicine was held at the headquarters
of Snibe in Shenzhen. The conference was jointly organized by the International Federation of Clinical
Promotion of T8 total laboratory automation, coagulation analyzer, and
Chemistry and Laboratory Medicine (IFCC) and Snibe, and invited 14 lecturers and over 300 participants.
electrolyte analyzer
The conference was honored to have the attendance of Professor Tomris Ozben (President of the IFCC),
Professor Khosrow Adeli and Maurizio Ferrari (former Presidents of the IFCC), and Professor Mario Plebani
In Sep. 2025, the 14th National Conference of Clinical Laboratory Management (NCCLab), organized by
(President of the European Federation of Clinical Chemistry and Laboratory Medicine [EFLM]).
the Chinese Hospital Association, was held in Chengdu. As an important academic exchange platform
in the field of clinical laboratory management in China, the Company made a stunning appearance at
the conference with a series of high-quality laboratory solutions and disease diagnosis and treatment
solutions, including SATLARS T8, the high-speed fully-auto electrolyte analyzer Biossays E6 Plus, and the
high-speed automated coagulation analyzer Hemolumi H6.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality and Safety and Innovation Management Marketing Quality
Customer Service Quality
Enhancing Snibe's brand influence through participation in international
exhibitions
In 2025, the Company participated in more than 140 international exhibitions worldwide, including
important industry platforms such as Medlab Middle East, EUROMEDLAB, ADLM, and Medica. On these
With the core strategic concept of "customer-centric, market-
stages, we systematically showcased cutting-edge laboratory technologies and innovative solutions, and
collaborated closely with global partners to address real-world challenges in the diagnostics field and oriented", Snibe keeps optimizing customer service solutions
actively shape the future direction of medical diagnostics. in all aspects by understanding customer needs, timely
responding to customer complaints, providing professional and
accurate services, and investigating customer satisfaction, so
as to provide customers with safe, reassuring, and innovative
products and services.
Customer service management and capabilities >
We practice the "service +" concept to continuously improve customer service experience, and provide carefree services
Responsible marketing training > for customers. We have formulated and implemented management systems such as the "Control Procedure for Servicing
Activities" to standardize the customer consultation and complaint handling process. Through systematic training and
The Company highly values the professional and academic capabilities of its marketing team. It has established a systematic, professional guidance, we continuously strengthen the team's professional ability and service awareness, and optimize the
regular, and effective training system that closely aligns with business strategies and effectively empowers the marketing quality of customer service.
frontline and support teams.
By 2025, the Company has built 190 service stations and upgraded on-site services in various regions across China, ensuring
In 2025, the domestic marketing center organized 54 regular training sessions, covering areas such as promotion strategies, customer response in 1–2 hours. To help technical engineers in different regions solve customer problems in a systematic way,
case sharing, knowledge training (luminescence, instrumentation, biochemistry, coagulation), and policies. Details are as we have developed the remote service system Snibe Link on our own to ensure a comprehensive and professional customer
follows: service. We are committed to providing customer-centric, rapid?response, and professional services to create worry-free and
value-added experiences.
The domestic marketing center has established a weekly, fixed-time joint training mechanism for the three teams (product
managers, sales personnel, and technical service engineers) to ensure information synchronization. The training content In overseas markets, Snibe implemented regional management with independent marketing, after-sales, market, and
includes: (1) product and technical knowledge, with in-depth training on clinical applications, report interpretation, and business for each region. Product sales and after-sales personnel are better connected to improve the regional product and
promotional advantages across six major areas, including bone metabolism, hypertension, and tumor biomarkers; (2) service performance. More foreign technical service personnel were recruited to ensure timely response to the urgent needs
interpretation of market dynamics and policies, with timely launch of courses on the rationale for test panels; (3) regular of distributors and end customers. As we expand our product lines, the number of overseas channels is also expanding
sharing of excellent promotion cases as well as distributor cultivation and benchmark hospital construction experience; in terms of both breadth and depth to bring quality products and services to more customers across the world. In major
(4) regular special strategy training for regional directors, deputy directors, and other management personnel to unify the countries and markets, the Company strengthens localization through the establishment of overseas subsidiaries. Up to
promotion consensus of regional leaders and ensure the accurate implementation of strategies. now, we have set up overseas subsidiaries in 16 countries. By recruiting local employees and applying for product circulation
licenses, overseas subsidiaries boost localized operations for more meticulous and comprehensive market coverage and
To ensure training effectiveness, the domestic marketing center adopts the "Learn?Test?Evaluate" approach. Post?training premium service for end customers.
tests are released via an online platform to enable immediate assessment of learning outcomes. By analyzing the distribution
of test scores, the center continuously refines training content and formats to ensure high relevance to actual work.
Product Quality Focusing on R&D Supply Chain Responsible Customer Service
and Safety and Innovation Management Marketing Quality
Customer satisfaction >
We truly adhere to the principle of delivering timely, efficient, dedicated, professional, thorough, and quality service to
customers. In case of any product problems, customers can get in touch with us through the "400" hotline, official mail,
and "External Information Feedback Form" on the official website. In addition, our technical service personnel strictly
follow Snibe's "Control Procedure for Feedback and Complaint Handling" for closed-loop management through regular
maintenance & customer visit and timely communication with customers. In 2025, 100% of the complaints received have been
handled, with a customer satisfaction rate of 100%.
We regularly conduct customer satisfaction surveys to understand the opinions and suggestions of customers on the
Company's products and services. In 2025, the domestic and foreign customer satisfaction reached more than 98%.
Improving customer service capabilities > PROMOTING GREEN
We maintain proactive two-way communication through a customer-centric approach to deliver sustained customer OPERATION
empowerment. ISO 15189 is an internationally recognized standard for quality and competence management in medical
laboratories. To help the medical laboratory departments establish a standardized quality management system and improve Major issues
the accuracy and mutual recognition of test results, we have provided ISO 15189 full-process support. This year, we continued · Addressing climate change
to provide ISO 15189 training and guidance to end customers in various regions, and built a combined online and offline · Emissions and waste management
platform for specialized training and exchanges, to fully empower customers to apply for accreditation. During the daily · Environmental management
service process, we discussed with laboratory teachers the problems and questions encountered in the validation analysis, · Resource management
to enhance their understanding of immunoassay product applications, help them master product applications and analysis · Energy management
validation methods, and improve laboratory quality management.
We attach great importance to the construction and training of technical service engineers. In 2025, we organized training
for domestic technical service engineers and provided on-site and online training for technical service engineers of overseas Alignment with Sustainable Development Goals (SDGs)
agents to comprehensively enhance their professional service capabilities. At the same time, through the "Snibe Forum"
online platform, we delivered knowledge to technical service engineers of our agents to promote their understanding of the
latest product-related information. On this platform, product-related information is constantly updated, and those engineers
can learn to operate the product quickly.
Snibe deeply practices the concept of sustainable development,
strictly aligns with environmental protection, conservation, and safety
production management standards, and continuously strengthens
the construction of its environmental and occupational health and
safety management system. We integrate the concepts of green
operation and safe production into all aspects of daily operations.
While ensuring employee safety and health, we strive to create an
efficient and environmentally friendly operation model, promoting
the deep integration of green development and safe operation.
Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation
Environmental and occupational health and safety management initiatives >
Environmental and Occupational Area Initiatives
Health and Safety Management
Environmental Waste management: Strictly implement the "Wastewater, Emissions, and Noise Management
management System" and the "Environmental Protection and Harmless Treatment System", and implement
classified storage, compliant disposal, and full-process monitoring of various wastes
generated from production and daily activities, ensuring full compliance with environmental
regulations and effectively safeguarding the environment.
Employee safety and environmental protection constitute the Resource and energy management: Continuously implement the "Resource and Energy
cornerstone of our continuous and stable development. Snibe Consumption Control Management System" to regulate employees' practices in conserving
has always adhered to the policy of "Environment protection, water and electricity. Post water and energy conservation signs to improve employees'
health and safety, compliance with regulations, and sustainable awareness of energy saving and emission reduction. Implement quota control for office
supplies. Integrate green design concepts into product design and production processes, and
development" to continuously strengthen the Company's overall
optimize the use of raw and auxiliary materials to reduce resource waste at the source.
safety and environmental protection construction. Snibe maintains
strict adherence to laws and regulations like the "Labor Law of the Hazardous waste management: Establish the "Hazardous Waste Management System" to
People's Republic of China", the "Environmental Protection Law of clarify the requirements for identification, classification, labeling, storage, transfer, and
the People's Republic of China", the "Safety Production Law of the disposal of hazardous waste. Maintain hazardous waste management records, implement
People's Republic of China", the "Fire Control Law of the People's the declaration and transfer manifest system, and eliminate environmental risks.
Republic of China", and the "Law of the People's Republic of China
Health Domestic water management: Establish the "Management System of Drinking Water for
on Prevention and Control of Occupational Diseases", and has
management Domestic Use" to clarify water quality testing standards for domestic drinking water tanks,
developed relevant supporting management systems according limits for key indicators, and water quality testing standards for direct drinking water.
to those laws and regulations and internal management needs to Commission external agencies to conduct water quality testing biannually, entrust third-
continuously improve environmental and occupational health and party agencies to inspect water fountains routinely, and clean the internal tanks of water
safety management. dispensers quarterly, ensuring that the Company's domestic drinking water fully complies
with the national standards for drinking water quality.
In 2025, the Company invested 4.58 million yuan in environment Occupational health management: Establish the "Management System for the Prevention
and occupational health and safety. and Control of Occupational Diseases". Sign the "Job-Specific Occupational Disease Hazards
Notice" with employees in high-risk positions, which clearly outlines job-related hazards.
Provide compliant and necessary personal protective equipment to all employees in high-
risk positions. Conduct annual monitoring of occupational hazard factors. Organize pre-
employment, in-service, and post-employment occupational health examinations for
employees in high-risk positions. Maintain employee occupational health records to timely
identify and address occupational health issues.
Canteen safety management: Establish the "Canteen Management System" to strengthen
canteen hygiene management. All the canteen staff are on duty with certificates.Conduct
Environmental and occupational health and safety management policy and objectives > regular inspections of food quality and hygiene management. Develop record forms for key
steps in the meal preparation process to ensure full traceability and risk control of canteen
Policy: Environment protection, health and safety, compliance with regulations, and sustainable development. management. Formulate a special emergency response plan for food safety, clarifying
Objectives: emergency response procedures, responsibilities, and handling processes for sudden
(1) Zero fire incidents incidents such as food poisoning.
(2) Zero chemical leaks and explosions
(3) Zero work-related fatalities or serious injuries Work?related injury management: Strictly implement the "Work-related Injury Management
(4) Zero occupational diseases System" to ensure proper reporting, investigation, identification, and medical treatment
procedures for work?related injuries, safeguarding employees' legitimate rights and
interests.
Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation
Area Initiatives
Emergency Emergency procedure management: Establish the "Emergency Preparedness and Response
Addressing Climate Change
management Control Procedures" to define the organization process, evaluation criteria, and improvement
mechanisms for emergency drills, and standardize the drill record template, promoting the
standardization and traceability of emergency management. Focusing on major risks such
as fire and hazardous chemical leaks, regularly organize comprehensive emergency drills
involving multiple departments to test the effectiveness of emergency plans and improve
employees' capabilities in emergency evacuation, initial response, and coordinated action. Snibe recognizes that the physical impacts of global climate
change and mitigation actions may pose significant risks or
Emergency resource management: Strictly implement the requirements for medicine create opportunities for our business. During the reporting
allocation, inspection, replacement, and documentation as specified in the "First Aid Kit and period, we identified relevant entity risks, transformation risks and
Medicine Management System" to ensure that first aid medicines and equipment in all areas
opportunities based on the business development and operation
are always in good condition and ready for use. Establish a first-aider team with basic first-
of the Company, and formulated corresponding countermeasures.
aid knowledge and skills.
Safety Equipment safety management: Establish various safety operation procedures and safety Type Influencing factors Specific impact Countermeasures
Management management systems, strictly implement pre-employment safety training, and ensure that
special equipment operators/special operation personnel hold valid certificates. Regularly Heavy rains, Snibe operates in a coastal city, We actively monitor climate trends and have
Entity risk
inspect and maintain production equipment, electrical wiring, and safety protection facilities typhoons and where increased frequency or developed an extreme weather emergency
to ensure the safe and stable operation of equipment and facilities. other extreme intensity of extreme weather events, response plan tailored to local conditions.
weather occur like heavy rains and typhoons, may We pay close attention to weather warning
Hazardous operations safety management: Establish the "Hazardous Operations frequently or disrupt facility power supply, leading information, and implement the following
Management System" to improve the approval and management requirements for high- increase in to water/power outages or damage preventive measures prior to forecasted
risk operations such as hot work, high-place work, and confined space work. Strengthen intensity to warehouses and equipment. Such extreme events: conduct safety inspections,
pre?operation risk identification, safety briefings, and implementation of protective risks threaten both property security clear drainage systems, repair roofs,
measures, and assign dedicated personnel for on?site supervision to ensure that the entire and our operational stability. reinforce perimeter walls, install water
process of hazardous operations is under safe control. barriers, strengthen ventilation, enhance
circuit leakage protection, improve
Hazardous chemicals safety management: Strictly implement relevant hazardous firefighting capacity, etc.
goods management systems, fully standardizing the management requirements for the
classification, storage, labeling, use, and waste disposal of hazardous chemicals. Assign Energy prices At present, Snibe's main energy The Company has proactively implemented
Transformational
dedicated personnel to manage and document chemicals inventories, deploy firefighting rise as countries consumption relies on externally energy management strategies, including
risk
facilities and emergency response equipment, and regularly inspect their effectiveness. respond to climate sourced electricity. Environmental technology upgrades, source-level energy
change protection regulations are becoming consumption controls, intensified energy
Fire safety management: Strictly abide by relevant fire safety regulations and systems. increasingly stringent, with national conservation and emission reduction
Establish the "Fire Equipment and Facilities Management System" to clarify the organization and local governments rolling out propaganda, etc. to reduce energy
and implementation of daily fire safety management. Equip all areas with appropriate fire policies to restrict corporate carbon consumption and carbon emissions.
equipment, emergency exit indicator lights, etc., as required. Regularly conduct inspections emissions. Rising fossil fuel prices
and maintenance of fire equipment, and organize company?wide fire drills and fire safety have also driven up energy-related
training. operational costs.
Investors are Snibe recognizes that domestic and The Company has actively responded to
increasingly international investors prioritize investors' concerns, and voluntarily initiated
focused on transparency in greenhouse gas climate risk identification, greenhouse
corporate climate (GHG) emissions and emission gas emission management and other
action reduction targets. Failure to actively programs for disclosure. Moving forward,
manage GHG emissions could lead the Company will further develop GHG
to ESG rating downgrade, negative reduction objectives in line with the needs
publicity, reputational damage, of enterprise development.
and ultimately restricted financing
channels and higher capital costs.
Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation
The energy usage of Snibe in 2025 is detailed as follows:
Type Influencing factors Specific impact Countermeasures
Opportunity Climate change Global climate and environmental Snibe is closely tracking diagnostic
leads to increased shifts, particularly rising demands linked to climate-sensitive
demand for new temperatures, are increasing the diseases and proactively advancing R&D
Purchased electricity Natural gas Gasoline Diesel
products likelihood of infectious disease of targeted testing products.
outbreaks and respiratory health
risks, which creates new product
opportunities for IVD companies. kWh cubic meters tons tons
Climate change Reduced energy and resource Through energy conservation and
policies promote consumption lowers both corporate emission reduction initiatives, including
technological emissions and operational costs. By technological transformation and
upgrading of adopting more efficient production equipment upgrading, the Company Snibe's carbon emission reduction target: To maintain a stable carbon emission intensity before the completion of Phase V of
enterprises and technologies, the Company can continuously improves energy the R&D and production base, and to achieve a steady decline in carbon emission intensity after the completion of Phase V
increase benefits increase production capacity and and resource utilization efficiency, and the normal operation of the R&D and production base. The main basis is that Phase IV of the R&D and production base will
revenue while enhancing resource achieving cost reduction and efficiency be completed in 2025 and the base will then be put into use. With expanding business operations, electricity consumption is
efficiency. enhancement. expected to rise significantly year-on-year, creating substantial short-term pressure on carbon intensity metrics.
The Company's greenhouse gas emissions predominantly stemmed from the utilization and consumption of electricity,
natural gas, gasoline, and diesel in its production and operations, direct emissions resulting from the escape of refrigerants,
and indirect emissions resulting from the consumption of purchased electricity. During the reporting period, we commissioned
SGS, an international authoritative certification body, to carry out a comprehensive and detailed greenhouse gas verification
audit, and obtained the ISO 14064-1:2018 Greenhouse Gas Verification Statement Certificate issued by SGS.
In 2025, the total carbon dioxide emissions (Scope 1 and Scope 2) resulting from the Company's operations amounted to Green Operation
while indirect emissions (Scope 2) stood at 14,481.52 tons of CO2 equivalent. The carbon emission intensity was 0.0373tons of
CO2 equivalent per 10,000 yuan ① .
Rigorously adhering to the "Water Pollution Prevention and Control Law of
the People's Republic of China", the "Law of the People's Republic of China on
Total emissions of Scope 1
Direct emissions (Scope 1) Direct emissions (Scope 2) and Scope 2 Carbon emission intensity
the Prevention and Control of Atmospheric Pollution", the "Law of the People's
Republic of China on the Prevention and Control of Environment Pollution Caused
by Solid Wastes", the "Regulations on the Administration of Medical Wastes", and
tons of CO2 tons of CO2 tons of CO2 tons of CO2
equivalent equivalent equivalent equivalent/10,000 RMB
other laws and regulations, the Company has formulated management systems
such as the "Control Procedure for Environmental Issues", the "Resource and
Energy Consumption Control Management System", the "Wastewater, Emissions,
and Noise Management System", and the "Hazardous Waste Management
System", so as to effectively utilize resources and energy and strictly oversee the
disposal process of hazardous wastes. The Company has not been listed as a
key pollutant discharge entity by the environmental protection authority. In 2025,
① Direct emissions (Scope 1) encompass emissions directly generated by the Company through the consumption of fossil fuels, including gasoline, diesel, and natural
gas, as well as direct emissions resulting from escape of refrigerant. Indirect emissions (Scope 2) include emissions resulting from the consumption of purchased the Company did not violate any environmental law or regulation, and was not
electricity by the Company. Total emissions represent the aggregate of direct and indirect emissions. The accounting methodology for electricity emission factors primarily
references the national average CO2 emission factor for electricity outlined in the "Announcement on Release of 2023 CO2 Emission Factor for Electricity", issued by the
subject to administrative penalties by the environmental protection authority.
Ministry of Ecology and Environment of the People's Republic of China on Dec. 31, 2025. Additionally, calorific value coefficients and emission factors for other energy
sources are mainly derived from the "Guidelines for Compiling Provincial Greenhouse Gas Inventory" and the "General Rules for Calculation of the Comprehensive Energy
Consumption".
Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation Environmental and Occupational Health and Safety Management Addressing Climate Change Green Operation
Emissions and waste management >
The Company places emphasis on fostering water conservation awareness among all employees. Through various means
Wastewater management such as posting water conservation slogans in office areas and sending internal notices, we advocate employees adopting
All sewage undergoes treatment following the principles of "rain and sewage diversion, collection at source, and reuse". good water-saving habits and guide them to embrace the concept of "taking pride in saving water and feeling ashamed of
Snibe implements environmentally friendly sewage management practices. Wastewater is categorized into rainwater, wasting it", collectively creating a green, low?carbon, and resource?conserving office environment.
domestic sewage, and production wastewater by source. Following a classified management approach, we collect each type
of wastewater accordingly. The sources of liquid medical waste and air filtration wastewater are collected and managed Focusing on water conservation and efficiency improvement, we proactively optimize water management measures. By
by accredited facilities. Meanwhile, the reject water without any chemical reagents and additives generated during the scientifically adjusting the operating pressure of water supply equipment and rationally controlling the water pressure
preparation of purified water is directed to a dedicated reject water recovery pool for toilet flushing and park irrigation, and and volume of faucets in restrooms, water consumption is effectively reduced without compromising employees' normal
discharged from the municipal domestic wastewater pipe network into the Shatian Water Purification Plant, contributing to water needs. This also reduces the operating load of basement water supply equipment, achieving dual benefits of water
resource conservation and waste reduction. conservation and equipment maintenance. In the Company's daily operations, the reject water generated mainly comes from
the purified water preparation process. The quality of this reject water has been tested and fully complies with the "Reuse of
Waste gas management Urban Recycling Water — Water Quality Standard for Urban Miscellaneous Use" (GB/T 18920-2020). Adhering to the principle
All waste gases produced by the Company are subject to the principle of "classified collection, centralized treatment, and of resource conservation and waste reduction, we have installed reject water storage tanks for recycling and reuse. Currently,
standards-compliant discharge". The production waste gases are treated through the waste gas treatment facility to meet 100-cubic-meter and 180-cubic-meter reject water storage tanks have been installed to supply water for toilet flushing and
regulatory standards before discharge, with regular emissions testing conducted. Independent waste gas collection covers park irrigation in the Company's Phase II and Phase III parks, respectively, effectively reducing tap water consumption.
and fume hoods are installed in production workshops and locations or areas where waste gas is generated within each
production line. The waste gas treatment device is equipped with activated carbon boxes and spray towers to ensure that We prioritize water balance testing as a cornerstone of water resource management, and conduct systematic testing,
laboratory waste gas is discharged in compliance with environmental standards. The flow directions in waste gas collection data collection, and analysis to establish precise water usage equilibrium. By scrutinizing every aspect of water usage
pipelines are clearly marked, and regular testing of waste gas by third-party institutions ensures alignment with relevant and optimizing processes with data-driven insights, we ensure stable operations while maximizing water efficiency and
laws and regulations on emissions. conservation.
Waste management In 2025, the Company's total water
Snibe has established a dedicated task force for environmental pollution prevention and control to perform classified Volume of reject water
Total water intake Water intake intensity recovered
intake amounted to 250,223 cubic
management of medical and hazardous wastes. Medical wastes, including infectious waste, sharps waste, and chemical meters,with a water intake intensity
waste, are centrally collected in specialized medical waste bins, and then disposed of by accredited facilities. The ten types of 0.5467 cubic meters per 10,000
cubic meters m3/10,000 RMB cubic meters
of hazardous wastes, including waste activated carbon, waste engine oil, waste lamp tubes, waste circuit board, waste yuan, and 21,679.7 cubic meters of
thermometer, waste ink carbon ribbon, waste rust-proof oil, waste chemicals, waste packaging, and spray tower wastewater, reject water recovered.
are centrally transported and disposed of by third-party organizations after collection.
Energy management
The Company actively implements the requirements for solid waste pollution prevention and control, fully promotes the The Company actively controls the rational use of energy, continuously enhances energy efficiency through technological
domestic waste classification system, and continuously advances the refined and eco-friendly management of solid wastes. advancements, equipment upgrades, and various measures, and strengthens the publicity and practice of green concepts to
For general solid wastes (domestic waste, kitchen waste, etc.) generated in daily operations, the Company strictly implements maximize energy efficiency.
classified management and entrusts qualified third-party organizations to carry out standardized transportation, utilization,
and disposal. At the same time, the Company rigorously reviews the technical capabilities of the entrusted parties to ensure To ensure electricity safety, we prioritize core facilities such as generator sets and power supply and distribution systems
full?process compliance. Recyclable materials such as office waste paper and cardboard are handed over to professional in routine inspections, and conduct comprehensive maintenance regularly. Through continuous routine inspections and
recycling facilities for resource utilization. preventative maintenance, we focus on operating conditions and circuit safety, and promptly replace aging or damaged parts
and components to eliminate safety hazards at the source and ensure the stable and efficient operation of the power system.
To further enhance employees' awareness of waste classification and improve the accuracy of waste disposal, the Company A comprehensive survey of primary, secondary, and terminal power distribution cabinets is conducted, and standardized
continuously optimizes the classification facility configuration and signage within its premises. For domestic waste and signs are posted to clearly distinguish between daily and emergency power supplies, preventing the emergency power
kitchen waste on each floor, the layout and specifications of bins have been specially upgraded to improve their visibility supply from being occupied and enabling rapid identification and response during emergencies.
and ease of disposal. A regular waste battery recycling mechanism has been established, with dedicated recycling bins
placed at fixed locations. The waste battery collection and disposal process has been standardized to reduce the potential We strengthen energy?saving awareness among all employees by posting slogans and sending notices to promote behaviors
environmental impact of heavy metals and other pollutants. such as saving electricity, double?sided printing, turning off lights when leaving, saving water, and actively reporting water
leaks. Signs are posted on switches and air conditioner panels to remind employees to use air conditioners scientifically: set
Resource and energy management > to no lower than 26 ° C in summer and no higher than 20 ° C in winter. Employees are guided to start with small actions and
jointly create a green office environment.
Water resource management
The Company rigorously regulates water resource usage, increases the proportion of recycled water, and enhances water We continuously promote refined management by scientifically regulating air conditioning units and reasonably setting
resource utilization efficiency through measures like water recycling and equipment adjustments. parameters based on seasonal changes and office needs. While ensuring office comfort, this approach maximizes
A regular inspection and maintenance mechanism for water facilities has been established and imp operational efficiency and reduces power consumption, achieving a balance between comfort and energy efficiency. For key
roved, incorporating key water facilities such as domestic water tanks and solar hot water systems into routine inspections. areas such as the Phase III plant's special workshops and underground garages, the lighting on/off times and brightness are
Comprehensive inspections and maintenance are carried out regularly, focusing on facility operation stability and pipeline scientifically adjusted to eliminate the phenomenon of "lights left on all the time", ensuring efficient use of lighting resources.
sealing. Aging or damaged parts and components such as valves, pipes, and faucets are replaced promptly to eliminate A centralized control device is installed at charging stations of underground garages, which is linked with the mobile phone
leaks at the source, ensuring that all facilities remain in good working condition, thereby guaranteeing water safety and to set a scheduled shutdown time, thereby avoiding a potential safety hazard and power waste caused by long-term standby
efficiency. A remote smart meter has been installed on the master water meter to monitor the water consumption in real time charging. The time-controlled system is deployed for courtyard lights, parking lot lights, and LOGO lights in the parks,
through the intelligent system, so as to effectively avoid manual meter reading errors, quickly detect abnormal water use, enabling precise remote control via mobile phones to significantly reduce energy consumption. Solar panels are regularly
and timely troubleshoot water leaks or equipment failures. cleaned and maintained to improve thermal conversion efficiency and maximize green energy benefits.
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
Attraction and Retention of Talents
TALENT
EMPOWERMENT
Major issues Diversity and equal employment >
· Diversity and equal employment
· Employee rights and benefits Equal employment
· Employee training and developmentt In strict accordance with laws and regulations such as the "Labor Law of the People's Republic of China" and "Labor Contract
· Occupational health and safety Law of the People's Republic of China", Snibe has formulated internal systems such as the "Human Resources Control
Procedure", "Employee Handbook", "Employee Internal Transfer Management System", and "Intern Management System"
to standardize the recruitment and talent management process, and build a high-quality and diversified talent team. It
is clearly stated in the "Human Resources Control Procedure" that Snibe prohibits the employment of child labor, opposes
discrimination in gender, health, and age, advocates diversity, and offers equal opportunities for every employee and
Alignment with Sustainable Development Goals (SDGs) job seeker. It is also explicitly specified in the "Anti-Discrimination and Anti-Harassment Management System" that Snibe
prohibits unfair treatment of employees in the process of recruitment, training, promotion, etc. on the basis of race, social
class, nationality, religion, disability, gender, etc.
In 2025, Snibe embraced a "hard worker focused" concept for exploration and practice in such fields as talent organization
and management, workplace environment, corporate culture, remuneration and welfare, and training system. For the first
time, we built and launched a LinkedIn Life page, shaping ourselves into a quality employer. In addition, we received the
honor of "2025 Employer of Excellence in Occupational Credit" from Guangzhou Best Check Human Resources Co., Ltd.
Attraction and reserve of talents
Snibe values a well-layered talent pipeline by formulating comprehensive talent development strategies and exploring
flexible and diverse ways to absorb talents. On-campus and off-campus recruitment are two major ways Snibe brings in
needed talents.
For on-campus recruitment, we persist in working with universities on university-enterprise cooperation projects and
ensuring ongoing communication. At present, we have signed university-enterprise cooperation agreements with top
Talent is the core driving force for sustainable corporate development. Snibe
domestic universities and built internship & practice bases. Nearly 600 faculty members and students have visited Snibe in
consistently prioritizes its talent strategy as the key to overall development,
the past year. By establishing joint postgraduate bases and employment bases, as well as joint post-doctoral research bases
c o n t i n u o u s ly a d va n c e s t h e c o n s t r u c t i o n o f t h e e m p l oye r b ra n d , a n d
and employment bases, and holding lectures on career development in colleges and universities, we continue to deepen
comprehensively enhances the professional level of human resource management.
the university-enterprise cooperation, and have established long-term cooperation with many colleges and universities to
Embracing an open and inclusive philosophy, we have established diversified
provide internship opportunities for their students. There are more than 150 interns in the Company. We provide one-on-
talent recruitment mechanisms while protecting the legitimate rights and interests
one mentorship for interns who join early and prioritize full-time conversion opportunities for students who have excellent
of employees according to laws. By establishing a sound vocational training system
practice performance. These cooperation programs allow us to offer various practice and employment opportunities to
and clear career development channels, we create a fair and transparent growth
university students and help them transform theoretical knowledge into practical skills. In turn, this provides us with access to
platform for employees and fully stimulate organizational innovation vitality. We
a huge talent pool.
continuously improve the occupational health, safety management, and welfare
systems, and better bind employees and bring them happiness, so as to achieve
the value creation and common growth of the enterprise and its employees.
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
Employee rights and benefits >
To recruit off-campus talents, we not only work with mainstream recruitment platforms and experienced headhunting
institutions at home and abroad, but also encourage our employees to recommend potential candidates. An array of talent
Remuneration and welfare system
introduction channels helps to fuel our talent-driven development, foster a team of scarce cutting-edge talents, and integrate
To establish a fair and competitive remuneration system, effectively attract, retain, and motivate talent, and support the
excellent talents to fulfill our strategic goals.
achievement of strategic goals and sustainable development, the Company has formulated the "Employee Remuneration
Management System", providing employees with a competitive remuneration system. The Company implements a
Employee diversity
remuneration system based on job value and performance results. The total annual remuneration of an employee consists of
Snibe remains committed to building a workplace of diversity, equality, and tolerance. With a diversified and inclusive
"monthly base salary + allowances/subsidies + performance bonus". In addition, we provide employees with annual salary
recruitment policy, we gather together top talents from across the world and encourage employees with different
adjustment opportunities, and reward teams and individuals who are dedicated to their work, have outstanding abilities, and
backgrounds to give full play to their talents. We treat every employee equally and secure their rights and interests in
achieve remarkable results, in recognition of their exceptional contributions to the Company.
recruitment, promotion, development, remuneration, and welfare regardless of gender, age, race, nationality, etc.
According to national and local regulations, we ensure that our employees are entitled to statutory holidays and leaves,
We actively cultivate a diverse workforce and champion workplace inclusivity. We focus on empowering underrepresented
contribute to social insurance and housing accumulation fund for all employees, and provide comprehensive non?salary
groups and providing employment opportunities for individuals with disabilities. To respect the religious and cultural
benefits, including supplemental commercial insurance, annual checkups, health testing and consultation, festival activities,
differences of foreign employees, we provide dedicated prayer rooms in the Company, and assist foreign employees in
and team-building activities, to meet employees' physical and mental health needs. For our female employees, we not only
obtaining legal work permits and residence permits to ensure their legal employment in China. We offer re-employment
provide paid marriage leave, maternity leave, breastfeeding leave, and other holidays stipulated by national laws to female
opportunities for retired employees. Retirees are welcomed back and provided with competitive benefits while fully
employees of reproductive years, but also build baby care rooms for working mothers, offer yoga classes, and hold Women's
considering the operational needs.
Day and Mother's Day activities.
By the end of 2025, Snibe had 2,785 employees with 168 from minority groups, of whom 36.62% were female, and 30.27% of
managerial positions were held by women.
Statutory Benefits Employee Welfare Work-life Balance
● Statutory holidays ● Holiday allowance ● Library
● Statutory leaves, including sick leave, work ● Staff quarters ● Gym
injury leave, marriage leave, funeral leave, ● Staff canteen ● Yoga class
Male Male
prenatal check?up leave, maternity leave, ● Shuttle bus ● Basketball court
paternity leave, breastfeeding leave, and ● Annual lottery ● Team-building activities
Employees by Management by
Female gender Female gender
annual leave ● Commemorative gift ● Festival activities
● Social insurance, including pension, ● Activity funds ● Club activities
medical insurance, unemployment insurance, ● Assistance in employee's settling ● Amateur cultural activities
work-related injury insurance, maternity down
insurance, etc. ● Supplemental commercial
● Housing accumulation fund insurance
● Other statutory benefits ● Occupational health examination
● Health consultation hotline
Health lectures and free medical
clinics
Employees by Employees by
age educational
background
Over 50 years old Doctor's degree
Snibe cares about employees' life after work and offers a variety of cultural activities and holiday care activities. All
employees are encouraged to participate in such activities. Employee activities include:
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
● Snibe organizes online and offline activities during traditional holidays, annual celebrations, and annual meetings. During Employee care and communication >
festivals such as Women's Day, Dragon Boat Festival, and Mid-Autumn Festival, special activities are successively held,
including gamified check-in challenges, skincare classes, plaster printmaking, and lantern making. This year marked the Establishing multi-dimensional communication channels
Company's 30th anniversary. We organized a series of activities, including a fun sports meeting and a themed marketplace, Snibe values listening to employees' voices and fully respects their opinions and feedback. To facilitate communication
produced a 30th?anniversary promotional video, successfully completed the unveiling ceremony of the corporate culture between employees and the management, Snibe builds feedback platforms of different types at all levels for equal, efficient,
spiritual fortress and the departmental tree adoption activity, and customized anniversary T-shirts, refrigerator magnets, and and constructive communication within the Company.
exclusive name tags for all employees, further enhancing employees' sense of participation, honor, and belonging.
We conducted an annual satisfaction survey for all employees, covering eight dimensions: their own work, internal
● To promote the inheritance of Snibe's culture and the realization of its strategy, and to commemorate the hard work and communication and management, career development, work environment and office software, remuneration and welfare,
dedication of "Snibers", this year, we held an award ceremony for employees serving the Company for 15 years and above, and corporate culture, industry environment and company development, and overall satisfaction. This year, the employee
presented them with service commemorative coins and trophies. Commemorative coins were also given to employees who satisfaction rate was 89.2%. Through systematic categorization and data analysis of survey results, we identified that
had served the Company for 1, 3, 5, and 10 years. To foster a culture of relentless pursuit of excellence, the Company convened employees' concerns were primarily concentrated in three areas: remuneration and benefits, their own work, as well
the 2025 Annual Performance Review & Honors Gala to formally recognize individuals and teams who delivered exceptional as management and communication. This provides a data foundation and decision-making basis for further improving
impact on mission-critical initiatives this year. management and services. Based on employee feedback, we will continuously optimize our initiatives, enhance employee
satisfaction and well?being, and work together with employees to create a better working environment.
● To help employees relax and keep fit, Snibe has built an in-house gym, a yoga room, a library, a basketball court, etc.,
and employed external professional yoga teachers to regularly conduct yoga classes at the Company. In addition, football
and badminton courts rented outside the Company are also available on a regular basis, providing a platform for employees Feedback Platform Feedback and Communication Mechanism
to keep fit and enrich their spare time. In collaboration with culture and sports authorities, we organize free events such
as watching movies and stage plays, fostering a harmonious and healthy work atmosphere and continuously enhancing Employee Satisfaction We conduct an annual satisfaction survey for all employees and report the pooled
employee well?being. Survey survey results to the Company's management. Relevant departments are tasked with
implementation and progress tracking based on the Company's decisions.
● This year, we held a Family Day event for the first time, inviting employees' family members to visit the company, tour the
workplace, and experience the corporate culture, thereby strengthening family support for employees and enhancing their Regular Feedback Through our year-end performance appraisal process, we systematically gather the
sense of identification. In conjunction with the Pingshan District Party-Mass Service Center, we organized several employee Collection opinions or suggestions of all employees on all aspects of the Company's management,
social events to build a communication and dating platform for young singles, deepening the humanistic care for young and report them to the management, with designated departments tasked with
people. implementation and progress tracking. We collect feedback and recommendations
from new employees and reply to them through symposiums and other forms. We
● To help new employees get familiar with the parks quickly, better adapt to the corporate culture, and enhance sense of also interview employees who intend to leave to improve the talent retention plan in a
belonging, we presented the "Guide to Park Life" and explained it in person on the day of employment. We organized a targeted manner.
welcome party for fresh graduates to help them better know each other and blend in with the big family of Snibe.
Smart Park Platform We continue to optimize the Snibe Smart Park Online Platform, and encourage employees
to give feedback on the staff canteen, equipment repair and various park services
through the platform.
In-house Publication "The Snibers", an in-house magazine, serves as the main medium to promote corporate
culture and highlight our employees. It includes such columns as company news,
management policies, employees showcase, reflections on work, the voice, and spare
time life, which focus on listening to employees and uniting all together.
Dedicated Feedback A dedicated feedback email and an anonymous submission portal are available for
Women's Day activities Mid-Autumn Festival lantern making Commemorative Coin Award Ceremony Email and Anonymous employees to voice concerns or proposals. Management responses to substantive
Submission Portal suggestions will be fed back to the employees.
Department Meetings Heads of each department stay informed of employees' demands through department
meetings and annual performance talks.
Labor Union and Employees' Congress
The labor union at Snibe forms a bridge of communication between the management and general employees. The
Unveiling of corporate culture spiritual Anniversary basketball game Welcome party for fresh graduates Employees' Congress aims to protect the rights, interests, and welfare of employees and keep the company dynamic. The
fortress
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
We keep improving and optimizing various training systems and processes. Committed to "people?oriented, making the
Labor Union regularly holds the Employees' Congress as required and maintains close communication with all employees to
best use of everyone's abilities", we have put in place a training operation system that focuses on both "talent construction"
get them involved in the decision-making of important affairs. Rules and regulations are also being optimized and improved
and "product empowerment". A diverse training system of all layers and categories is being built, along with talent training
to better safeguard the rights and interests of employees.
mechanisms of all types, to fuel the internal business operation at all positions. A combination of both online and offline
training, including onboarding, induction/transfer training, external expert-led management training, special training for
In 2025, the Company held the Employees' Congress two times to review and approve systems such as the "Technical Grade
serving staff, and special training on quality, instrumentation, and safety production, improves employees' hard and soft skills
Evaluation Measures for Engineers in Domestic and Foreign Technical Service Departments" and the "Management Measures
and overall workplace capabilities, drives their career development, supports the Company's ongoing business expansion and
for the Professional Knowledge and Skills Assessment of Product Managers in the Domestic Market Department", further
optimization, and shapes a talent pipeline for continuous business development.
improving the talent evaluation and cultivation system. At the same time, the Congress successfully completed the election
of employee representative directors to the Company's board of directors, effectively guaranteeing employees' rights to
participate in the Company's democratic management and supervision. In 2025, we offered 33,899 training opportunities of 96,743 hours for our employees.
Talent introduction and retention for 2025:
Employee ability improvement >
New Employees Turnover Rate ①
All-round ability improvement
We have been developing and upgrading training courses that target and serve the company's development strategy and
business needs.
● Cultivation of fresh graduates
We have established a training framework for fresh graduates, including three stages: "entry", "growth" and "success". Group
training after joining the company helps new employees to get the basics of the company, swiftly learn and adapt to the
corporate culture, and complete the transformation from campus to workplace. Tutoring, job rotation, and panel discussions
enable fresh graduates to quickly fit into the team and master essential job skills. With the guidance of the direct supervisor
and tutors, these new employees can establish a solid groundwork for independently undertaking key tasks in the future.
● General knowledge and soft skills enhancement
Product basics popularization and work-related comprehensive soft skill enhancement are realized through Snibe Lecture
with the help of an online learning platform "DingTalk". Through years of continuous exploration and experimentation, we
have initially established a framework for general workplace knowledge and skills training. This year, we launched 37 online
courses across five series: AI, communication and presentation, medical science popularization, summary and reporting, and
four major chronic diseases. For the first time, we successfully repurposed online courses into offline courses, which became
highly popular upon release. A total of 40 sessions were held throughout the year, with more than 6,300 attendances and an
Employee Training and Development average learning time of approximately one hour per person, meeting employees' learning needs for general skills.
● Improved management capabilities
We have comprehensively strengthened the reserve and development of mid-level and frontline managers. This year,
we focused on carrying out special training on personnel management capabilities for the marketing team. For overseas
marketing centers, we specially hired external experts to conduct a 3?day full?time intensive training themed "Building High-
Performance Cross-Cultural Teams — Talent Identification and Utilization in Sales Teams". The training comprehensively
imparted experience and skills in talent "selection, utilization, development, retention, and motivation" to managers, from four
Training system >
dimensions: "managing goals, managing processes, managing capabilities, and managing willingness", thereby enhancing
the management capabilities of the marketing team. For the domestic marketing center, a two-day full?time intensive training
Diverse training system
themed "Annual Goal Management and Efficient Execution Workshop" was conducted by rehiring external experienced
Snibe believes that employee training boosts the corporate development. On top of the "Training Management System",
experts. The training covered four aspects: "understanding and upgrading of the manager's role, goal management and plan
Snibe has formulated a series of training management measures, detailed rules, and operational guidelines such as the
execution, team development and motivation, as well as communication skills and practical application". Managers were
"Operational Guidelines for the Implementation of Training Process" and the "Operational Measures for the Implementation
guided to engage in deep learning and self?reflection, supplemented by learning methods such as scenario simulations and
of Training System" to support and standardize training.
role?playing, which reinforced the training outcomes.
● Enhancement of professional skills
Leveraging our part-time internal trainer team and the "Cloud Classroom" online platform, we have launched a series
① Turnover rate = annual employee departures/average annual headcount
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
of training programs, including "Product Optimization and Upgrade", "Performance Verification", "Annual Rotational Qualification and talent recognition
Training", and "New Product Empowerment", thereby meeting employees' professional learning needs and solidifying their We have been developing and upgrading training courses that target and serve the company's development strategy and
understanding and knowledge of new products. This year, we have further expanded training programs on the themes business needs.
of "Quality, Instrumentation, and Safety", the "Medical Device Assembler·Job Level Certification" series, and the "Reagent
Production Quality and Efficiency Improvement" special program, to meet employees' more refined, deeper, and broader ● Support for employee qualification
needs for professional upgrading. What's more, we actively communicate with industry experts, suppliers and other partners, Snibe encourages and rewards all employees to take the exams for relevant skills certificates and gain post qualifications by
and host activities like "Clinical Testing Lecture", "Snibe Day", and "Inspection Industry Experts/Specialized Exchange Meeting" covering all associated costs, including exam fees and annual reviews. Employees participating in off-job training can also
to further meet the learning needs of personnel in specific functions/positions for "advanced, specialized, cutting-edge" get subsidies of transportation, catering, etc. By the end of 2025, employees had obtained more than 100 skill certificates,
knowledge, and provide support and momentum for internal technical reformation and product innovation. covering professional skill qualification certifications in fields such as special equipment safety, internal audit, medical device
lifecycle management, drug validation, electronic product testing, statistical technology application, metrological verification
In addition, we provide employees with more opportunities and platforms for learning and growth by investing more and and standard substance development, chemical management, corporate compliance, and occupational health.
more in talent cultivation and integration. In 2023, we were officially certified as a "Shenzhen High-skilled Talents Training
Base". In 2024, we received the "Top Ten Demonstration Carriers of Shenzhen Lifelong Vocational Skills Training" award from ● Assistance in talent recognition and professional title application
the Human Resources and Social Security Bureau of Shenzhen Municipality. These recognitions offer a promising platform for We assist qualified employees in applying for high-level talent recognition and professional titles under the talent policies of
future employee development and talent cultivation. local governments, and we encourage employees to further their professional competitiveness. We also hold skills festivals
with Shenzhen colleges and universities to identify the field-operational experts with excellent skills. In 2025, 54 employees in
the Company obtained professional titles in their respective fields.
Employee promotion and development >
Diverse promotion and development paths
To "make the best use of talents", we set up clear and detailed promotion channels for employees with a series of clear internal
promotion systems, including the "Rank Management Measures", "Rank Promotion Management Measures for Reagent R&D
Personnel", "Supplementary Rules for Promotion and Management of R&D Personnel", "Technical Grade Evaluation Measures
for Engineers in Domestic and Foreign Technical Service Departments", "Rank Promotion Management Measures for Product
Managers in Domestic Marketing Departments", etc. At the same time, the Rank Evaluation Committee, the highest authority
for rank promotion and development, has been established to ensure fair, reasonable, scientific, and compliant selection.
Snibe aspires to grow with employees together and set position requirements in line with the corporate goals and employee
career goals. Clear, exact, and fair career paths have been designed for employees of all ranks and all positions. We
encourage employees to leverage their talents and challenge new positions. We set three career development paths of
"expertise", "management", and "business" to provide fair and impartial career choices and development opportunities for
all employees. With the promotion method integrating "technical expertise" and "management ability", employees with
outstanding contributions or special talents are promoted more than one grade at a time, while employees with exceptional
comprehensive and professional ability are promoted and cultivated, so as to guide employees to leverage their own edges in
enhancing professional skills and overall competitiveness.
To promote talent mobility, we implement a flexible internal transfer mechanism, regularly monitor and evaluate the
work performance and professional skills of employees who wish to transfer and provide appropriate support. We offer
cross-departmental and cross-functional transfer opportunities to employees who are willing and qualified to transfer,
breaking down job restrictions, stimulating employee development potential, and enhancing organizational vitality and
innovation capabilities. Moreover, we continue to optimize the talent management by adjusting the existing rank evaluation
requirements, so that employees can have a clearer understanding of their development direction. The talent analysis report
and human resources management report of each center are regularly output, so as to timely identify and motivate employees
with outstanding work performance.
In 2025,100% of employees received year-end performance appraisals, and more than 80 employees applied for and
completed internal transfer.
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
Employee Career Development System
Occupational Health and Safety
Employee Career Employee
career development career
level path/level/ development
appraisal standard planning
Occupational health >
Snibe believes in "people first" in its management and always puts employee health in the first place. Various measures
are taken to safeguard the physical and mental health of employees. The Company strictly abides by relevant laws and
Where am I Career Where to go?
regulations on occupational health and safety like the "Safety Production Law of the People's Republic of China", and
development path How to go?
the "Law of the People's Republic of China on the Prevention and Control of Occupational Diseases", and has developed
management systems such as the "Control Procedure for Hazards", the "Management System for the Prevention and Control
of Occupational Diseases", and the "Work-related Injury Management System" to identify, analyze and manage potential risks
in daily operations and protect the health and safety of employees.
Employee Promotion Channels
Deaths from Serious injuries from Occupational injuries excluding Losses of working hours due
occupational injury occupational injury deaths and serious injuries to occupational injuries
Management path Professional Business
technology path path
hours
Deputy general Deputy general manager
Chief engineer
manager of marketing center
Occupational disease prevention and control
Director/deputy Staff engineer Regional deputy Snibe continuously regulates occupational health monitoring to prevent occupational diseases. The Human Resources
director director/director Department conducts statistical analysis and management of occupational hazards. During employee onboarding, the
department truthfully informs employees about the occupational disease hazards associated with their positions, including
Manager/deputy potential consequences, protective measures, and relevant benefits. The Company implements occupational disease
Senior engineer Regional manager
manager prevention measures and requires employees to sign the "Job-Specific Occupational Disease Hazards Notice".
Intermediate The Company sets up bulletin boards in prominent positions in the production workshops to issue rules and regulations on the
Supervisor District manager
engineer prevention and control of occupational hazards, operating procedures, emergency rescue measures for occupational hazards
accidents, and the detection and evaluation results of occupational hazards in the workplace. The Company organizes
occupational health examinations for employees who are exposed to occupational disease hazards and special operations in
Team leader/specialist Engineer Sales manager strict accordance with the relevant regulations based on the types of occupational disease hazards and the level of exposure.
The physical examination report is added to personal health records, and the employee is informed of the actual results of
occupational health examination.
Assistant/trainee Safeguarding physical and mental health
The Company places a strong emphasis on the physical and mental health of its employees, regularly organizes occupational
health checkups, and routinely conducts activities such as traditional Chinese medicine health lectures, free clinic services,
New employee and stress relief workshops. In collaboration with commercial insurance providers, the Company also offers health screenings,
including retinal scans and TCM pulse-taking machine assessments. A mental health hotline has been established to support
employees' overall well-being.
To ensure the hygiene of food and the safety of drinking water in the Company canteen, all canteen staff are required to be
Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety Attraction and Retention of Talents Employee Training and Development Occupational Health and Safety
certified and regularly inspect food quality and hygiene. Key aspects of the food service process are managed through record- drills comprehensively covered key risk scenarios. In addition to emergency drills such as fire evacuation, hazardous chemical
keeping forms to ensure full traceability. In addition, a food safety emergency plan has been developed, and procedures for accidents, highly toxic substances, and hazardous waste pollution disposal, we also organized specialized emergency
handling emergencies have been clearly defined. Regarding drinking water, clear testing standards and limit values for water drills such as dormitory fire emergency drills, heptafluoropropane gas extinguishing system emergency drills, and elevator
tanks and direct drinking fountains have been established. The Company regularly commissions external agencies to test accident emergency drills. These drills effectively strengthen the emergency response awareness and practical handling
water quality. Direct drinking fountains are cleaned at regular intervals and their filters are replaced to ensure that drinking capabilities of all personnel.
water complies with the national standards for drinking water quality.
Safety management >
Snibe always regards safe production as the lifeline of enterprise development, and unswervingly implements the
responsibility system for safe production. To fortify safety safeguards, the Company conducts regular safety awareness
campaigns and training programs. These initiatives systematically elevate employees' safety consciousness through multi-
dimensional and in-depth approaches, comprehensively enhance their occupational safety competencies, and effectively
reduce various safety risks.
Strengthening the foundation of safety
In terms of safety training and awareness building, the Company has established an education mechanism of "mandatory
training upon onboarding + annual refresher training". This year, a total of 6 special safety training sessions for new employees
and 2 safety retraining sessions for all employees were conducted, achieving full coverage of all positions. By leveraging
key occasions such as "Safety Production Month" and "Fire Prevention Publicity Month," and through various forms such as
knowledge lectures and case studies, we create a cultural atmosphere where "everyone talks about safety," continuously
strengthen the safety awareness and sense of responsibility among all employees, and build a solid ideological defense. Emergency Response Drill for Hazardous Chemical Leaks
In terms of special equipment safety operation and maintenance, the Company has established a management system
In May 2025, we conducted a special drill for hazardous
covering the entire lifecycle of equipment, strictly implements the daily inspection and regular maintenance system for
chemical leaks in key areas such as hazardous chemical
elevators, and completes the review and verification of special equipment safety standardization certificates and the updating
warehouses and hazardous waste storage rooms.
of technical files to ensure that the equipment is always in a compliant, safe, and reliable operating state, eliminating
Prior to the drill, more than 1,000 personnel, including
potential hazards from the source.
warehouse managers, operators, and emergency
response team members, received systematic training,
At the level of fire safety management, the Company thoroughly implements the working policy of "prevention first,
which focused on the hazardous characteristics of
combining prevention and firefighting", continuously optimizes the configuration of fire protection facilities, establishes a
chemicals, safety identification, and emergency
"daily inspection, monthly testing, and annual maintenance" mechanism, and regularly conducts equipment function tests.
response procedures for leaks. The drill simulated
The Company strictly abides by the national regulations and standards to ensure that the fire passages in the office area are
the entire process of a leak accident, including its
unblocked, and standard fire protection facilities and equipment are well equipped. Designated personnel is responsible for
occurrence, reporting, initial response, and evacuation,
conducting regular inspections to eliminate potential safety hazards in a timely manner.
effectively strengthening the risk prevention and
collaborative response capabilities of key personnel.
In terms of hazardous goods management, the Company strictly implements effective control measures for hazardous
goods. We properly classify, store, and protect various chemicals, flammable and explosive materials according to their
specific characteristic. Hazardous chemical warehouses are equipped with adequate protective equipment, fire protection
and emergency response facilities, and have obvious warning signs. Hazardous chemicals are classified according to their Extreme Weather Emergency Response
characteristics and SDS documents are stored in the corresponding hazardous chemical storage cabinet, which is managed
and registered by designated personnel in accordance with the regulations. Hazardous goods are counted by warehouse In Sep. 2025, Super Typhoon Ragasa struck. The
keeper on a quarterly basis. Administration Department responded swiftly, forming
an emergency task force and inspection teams. We
In terms of emergency management, the Company establishes an emergency preparedness and response mechanism. We adhere to source control, thoroughly clean up sewers in
clearly define emergency response plans for various types of accidents, including fires, hazardous chemical accidents, and advance, reinforce objects on the ground and rooftops,
object strikes. In accordance with the requirements of the emergency plans, we equip ourselves with emergency supplies, and build a solid safety barrier. At the same time, we
equipment, or facilities, and designate the persons responsible for their daily storage and inspection. In terms of emergency strengthened routine precautions, conducted regular
resource allocation, we form a first-aider team and equip medical kits and first-aid equipment, among others. In terms lightning protection inspections, regularly maintained
of emergency evacuation, the signage management of safety exits and evacuation routes in office and production areas generator sets, and worked with professional third-
should be fully standardized to ensure that escape routes are clearly identifiable. The responsibilities of the floor supervisors party maintenance organizations to issue professional
and evacuation guides are clearly defined, establishing a well-defined emergency command system that provides a solid maintenance reports to ensure the safety and reliability
guarantee for the rapid and orderly evacuation of personnel in emergency situations. of emergency facilities and equipment.
Emergency drills and response
The Company consistently implements its emergency response plan system for safe production. In 2025, we organized more
than 20 emergency drills and specialized training sessions to enhance our practical emergency response capabilities. These
Industry Exchange and Cooperation Community Commonweal
Industry Exchange and Cooperation
FULFILLING SOCIAL
RESPONSIBILITY
Industry-University-Research collaboration and multi-center research >
Major issues
· Industry exchange and cooperation In active response to the "14th Five-Year Plan for Pharmaceutical Industry Development" and the "Healthy China 2030
· Community commonweal Planning Outline", Snibe has continuously focused on addressing the pain points and needs of front-line clinical and
laboratory medicine, and attached great importance to industry-university-research-hospital-application cooperation.
Snibe has joined hands with universities, hospitals, and enterprises for all-round cooperation targeting disease diagnosis
and treatment, medical technology development, IVD research and development, technology commercialization, and talent
training. By leveraging respective strengths, all parties aim to promote product diversification and technological innovation
in IVD. Amidst the national endeavor to prevent and control the four major non-communicable diseases, Snibe has carried
out relevant research with medical institutions to help early diagnosis and treatment of chronic diseases.
Alignment with Sustainable Development Goals (SDGs)
Multi-center Research on Screening of Aldosterone and Renin in Patients
with Primary Aldosteronism, Establishment of Diagnostic Cut-off Values,
and Clinical Application Evaluation
On Mar. 29, 2025, the "Multi-center Research on
Screening of Aldosterone and Renin in Patients with
Primary Aldosteronism, Establishment of Diagnostic
Cut-off Values, and Clinical Application Evaluation" and
the " Multi-center Research on Aldosterone and Renin
Reference Interval Establishment in Different Regions of
China" participated in and supported by the Company
While steadily advancing its own development, Snibe has never
were concluded in Shenzhen. This multi-center
forgotten to fulfill its corporate social responsibility. Relying on our
research has promoted the standardization of primary
competencies and technological expertise, we actively participate
aldosteronism screening and diagnosis in China, and
in industry exchanges and cooperation, promote the popularization
will help to further promote primary aldosteronism
of medical examination knowledge, and facilitate the overall
screening at the grassroots level.
development of the industry. We collaborate with multiple medical
institutions to conduct scientific research, promote early diagnosis
and treatment of chronic diseases, and continuously support scientific
research and education, contributing our efforts to the training of
diagnostic personnel and the advancement of medical research.
Industry Exchange and Cooperation Community Commonweal Industry Exchange and Cooperation Community Commonweal
Academic extension >
Supporting chronic disease management and value-based healthcare practices
Multi-center Research on the Clinical Application of High-sensitivity
China's healthcare system is undergoing profound changes. The comprehensive advancement of DRG/DIP payment reform
Troponin I Concentration and Changes in the Assessment of Acute
marks a shift in the healthcare value evaluation system from "payment based on quantity" to "pricing based on effectiveness,"
Myocardial Infarction
and the concept of value-based healthcare is gradually gaining popularity. The Company fully leverages its leading position
in the field of laboratory medicine to promote the exploration and practice of chronic disease management and value-based
healthcare. In 2025, the Company continued to conduct a number of chronic disease management activities, and the relevant
On Apr. 19, 2025, the Company held a launch meeting
conference convened experts and scholars from the field of laboratory medicine to discuss in depth the strategies, cutting-
in Nanjing for the "Multi-center Research on the Clinical
edge concepts, latest technologies and practical challenges of disease prevention and treatment, aiming to promote the
Application of High-sensitivity Troponin I Concentration
accurate diagnosis and clinical management of chronic diseases and contribute to the high-quality development of chronic
and Changes in the Assessment of Acute Myocardial
disease management in China. "Appropriate and precise" solutions are provided for achieving the strategic goals of "Healthy
Infarction," in which it participated and supported. This
China 2030".
multi-center research will combine machine learning
algorithms to transform static data into time-series
Participating in the preparation of laboratory medicine books and clinical manuals
dynamic, multi-modal diagnostic models, and develop
As the editor-in-chief, Snibe participated in the preparation of "Medical Laboratory Equipment and Application" (immunology
more flexible, accurate, and more suitable diagnostic
section, biochemistry section, laboratory intelligence and informatization section), "Expert Consensus on the Development
solutions for the Chinese population. This also marks a
and Evaluation of In Vitro Diagnostic Products", and "In Vitro Diagnostic Enterprise Operation and Management" led by
new milestone for the Company in the field of clinical
renowned experts in Chinese laboratory medicine, transforming our technical accumulation in chemiluminescence,
application research of myocardial biomarkers.
biochemistry, automated assembly line, reagent research and development, laboratory intelligence construction and other
fields into standardization knowledge and consensus. Through the authoritative and practical guidance of these publications,
the Company promotes the standardization of industry technology, makes the research and evaluation of in vitro diagnostic
products more in line with current needs, and contributes to the high-quality publication of innovative textbooks for the
cultivation of medical laboratory technology professionals under the background of new medicine.
In active response to the national policy on optimizing test panel profiles, the Company takes the lead in compiling the
"Handbook for Conducting Clinical Test Items" to assist medical institutions in conducting truly meaningful and clinically
valuable test items, as well as enabling precision testing for related disease screening, treatment, and prognosis, thus
empowering value-based healthcare.
Real-World Research on the Establishment of a Spectrum of Endocrine
Supporting clinical academic research
System Toxicity Related to Tumor Immunotherapy and Its Impact on Patient
By the end of 2025, Snibe users worldwide had published over 600 international journal articles and approximately 200
Clinical Outcomes
academic posters related to Snibe products. Snibe has partnered with several authoritative hospitals to conduct 16 medical
studies on its small molecule "Snibe-NACA" testing product, and 25 related academic papers have been published to date.
Extensive real-world customer research data shows that the "Snibe-NACA" testing technology effectively addresses clinical
On Dec. 14, 2025, our Company launched a "Real-
pain points and facilitates precise disease diagnosis and treatment.
World Research on the Establishment of a Spectrum
of Endocrine System Toxicity Related to Tumor
Popularizing laboratory knowledge
Immunotherapy and Its Impact on Patient Clinical
Actively promoting the popularization of clinical medical knowledge is an important part of our social responsibility as a
Outcomes" in collaboration with 20 top-tier tertiary
biopharmaceutical company. We popularize laboratory medicine knowledge through professional articles, popular science
hospitals. This multi-center research promotes a
posters, and online professional knowledge exchanges.
profound shift in cancer treatment from "disease-
centered" to "patient-centered" by systematically
The Company, in collaboration with DXY, conducted online academic exchanges through medical forums and organized 13
constructing a toxicity management model.
offline academic exchange conferences to popularize knowledge of laboratory medicine and promote industry exchange and
cooperation.
Industry Exchange and Cooperation Community Commonweal Industry Exchange and Cooperation Community Commonweal
Driving industry standardization >
Deeply engaging in the development of standardization organizations
The Company actively participates in the development of industry standardization organizations, takes the initiative to
participate in the work of standardization technical committees at all levels, and actively applies for committee member
qualifications, using its professional capabilities to help the industry and standardization work achieve high-quality
development. In 2025, the Company successfully joined two national and international counterpart standardization technical
organizations: Rao Jie was selected as a member of the WG3 (In Vitro Diagnostic Products Group) of the domestic technical
counterpart working group for ISO/TC212 Medical Laboratories and In Vitro Diagnostic Systems, and Du Kai was selected as
a member of the TC136 Clinical Laboratory Testing and In Vitro Diagnostic Test Systems. Leveraging its role as a committee
member, the Company will participate more deeply in industry standardization efforts and continue to contribute its
professional expertise to the industry's standardization and high-quality development.
Engaging in standards development and standard system establishment and revision
Snibe actively integrates itself into both domestic and international standardization systems. The Company not only
participates in the research of national and international standards, but also contributes to the formulation of national
standards, industry standards, and group standards in an all-round way. With excellent professional capabilities and
extensive industry experience, Snibe demonstrates its leadership in facilitating the mutual recognition of test results.
During the reporting period, the Company engaged in the development and collaborative calibration of 20 national
standards, national references, and international standards, led or participated in the drafting of 11 reagent-related
national standards, industry standards, and group standards, and established 1 reference method, further strengthening
the traceability consistency and result mutual recognition of the aforementioned diagnostic products. By doing so, scientific
In 2025, the Company's overseas marketing department leveraged the Company's self-owned media platforms to promote norms and guidance are in place for the industry development, effectively promoting the standardization process of the
laboratory medicine knowledge through promotional posters on the occasion of major global health awareness days, thereby industry.
fulfilling its corporate social responsibility.
During the reporting period, the development of standards and references, as well as the compilation of national/industry/
group standards that Snibe is involved in, include:
Type Assay Abbreviation Name Status
National HCG Human chorionic gonadotropin Collaborative assignment, uniformity and
standards stability tests completed; released.
FSH Follicle-stimulating hormone Collaborative assignment, uniformity and
stability tests completed; to be released.
TSH Thyroid stimulating hormone Collaborative assignment, uniformity and
stability tests completed; released.
tPSA Total prostate-specific antigen Collaborative assignment completed; to be
released.
fPSA Free prostate-specific antigen Collaborative assignment completed; to be
released.
IGF-1 Insulin-like growth factor-1 Periodic verification experiment completed
TNF-α Tumor necrosis factor-alpha Collaborative assignment completed; to be
released.
IL-6 Interleukin-6 Collaborative assignment completed; to be
released.
completed; to be released.
Industry Exchange and Cooperation Community Commonweal Industry Exchange and Cooperation Community Commonweal
Type Assay Abbreviation Name Status Type Name Sponsor Status
National PROG Progesterone Collaborative assignment and suitability Industry Cortisol testing kit Clinical Laboratory Testing and We participated in standard
standards study completed; to be released. standard In Vitro Diagnostic Test Systems drafting, and the standard
formulation (SAC/TC136) was submitted for approval.
TEST Testosterone Collaborative assignment and suitability
study completed; to be released. Group standard Vascular endothelial growth factor China Inspection and Testing We participated in standard
formulation assay kit (magnetic particle based Society drafting, and the standard
ALD Aldosterone Assignment and application preparation chemiluminescent immunoassay) was released in Jul. 2025.
stage
Immunoassay - evaluation of Chinese Society for We participated in standard
National Anti-HCV Hepatitis C virus antibody Collaborative assignment completed; to be measurement uncertainty Measurement drafting, and the standard
references released. was submitted for approval.
CMV IgM Cytomegalovirus IgM Collaborative assignment completed; to be Guidelines for construction and China Association of Productivity We participated in standard
antibody released. evaluation of smart laboratory Part Promotion Centers drafting, and the standard
B19 IgM Human parvovirus B19 IgM Collaborative assignment completed; to be
antibody released. Technical requirements for Hospital Management and As the deputy editor-in-chief,
information technology Information Technology we participated in standard
Toxo IgM Toxoplasma gondii IgM Collaborative assignment completed; to be construction of regional medical Construction Branch of the writing; drafting in progress.
antibody released. laboratories National Association of Health
Industry and Enterprise
Rubella IgM Rubella virus IgM antibody Collaborative assignment completed; to be Management
released.
Fully-Auto Chemiluminescence Standardization Working We participated in standard
HBs Ag Hepatitis B surface antigen Collaborative assignment completed; to be Immunoassay Analyzer Committee of China Association drafting, and the standard
(chemiluminescence) (chemiluminescence) released. for Promoting International was submitted for approval.
Economic & Technical
HBs Ag (rapid test) Hepatitis B surface antigen Collaborative assignment completed; to be Cooperation
(rapid test) released.
Establishment Development of a standard National Center for Clinical The method has been
International TNF-α Tumor necrosis factor-alpha Collaborative assignment completed; to be of test reference reference method for FT3/FT4 Laboratories, Guangdong established and validated;
standards released. method small molecule free hormones Provincial Hospital of Traditional the article is in the process of
by liquid chromatography-mass Chinese Medicine publication.
spectrometry
Type Name Sponsor Status
National Automatic sample processing system for Clinical Laboratory Testing We participated in standard
standard medical use and In Vitro Diagnostic Test drafting, and the standard
formulation Systems (SAC/TC136) was released in Oct. 2025.
In vitro diagnostic medical devices Clinical Laboratory Testing We participated in standard Driving laboratory quality management standardization
— Information supplied by the and In Vitro Diagnostic Test drafting, and the standard Laboratory quality management and testing competency serve as fundamental safeguards for achieving inter-institutional
manufacturer (labelling) — Part 1: Terms, Systems (SAC/TC136) was submitted for approval.
consistency in diagnostic outcomes, forming the essential basis for mutual recognition of test results. ISO 15189 is currently
definitions and general requirements
the most authoritative international standard for accreditation of medical laboratories. Guided by national policies, the
Industry 17 α-hydroxyprogesterone assay kit Clinical Laboratory Testing We led the standard drafting, Company has launched a standardized laboratory construction solution, which covers ISO 15189 accreditation services,
standard (labeled immunoassay) and In Vitro Diagnostic Test and the standard was quality supervision services, and grassroots quality improvement services, comprehensively covering the multi-dimensional
formulation Systems (SAC/TC136) released in Jun. 2025. standardized construction needs of laboratories and promoting the "standardization" of laboratories.
In vitro diagnostic medical devices — Clinical Laboratory Testing We participated in standard
Practical guidance for establishing and In Vitro Diagnostic Test drafting, and the standard To promote the adoption of ISO 15189 certification, ISO 15189 training and guidance were provided to 82 hospitals in 2025,
metrological traceability of values — Part Systems (SAC/TC136) was submitted for approval. of which 87% were tertiary hospitals. The Company continues to improve service solutions, driving the standardization in the
strategy".
Blood ammonia test kit Clinical Laboratory Testing We participated in standard
and In Vitro Diagnostic Test drafting, and the standard
Systems (SAC/TC136) was submitted for approval.
Industry Exchange and Cooperation Community Commonweal Industry Exchange and Cooperation Community Commonweal
laboratory medicine in underdeveloped regions. We have systematically shared in vitro diagnostic solutions and localization
practices suitable for resource-constrained environments, and held practical discussions on key issues such as improving
the capabilities of primary laboratories, optimizing public health screening networks, and strengthening personnel training
Medical laboratory accreditation and quality management training course and technology transfer. By building an open and collaborative dialogue platform, Snibe is committed to promoting the
widespread availability of appropriate technologies, facilitating knowledge sharing and capacity building in the field of
laboratory medicine between China and Africa, and contributing professional expertise to improving healthcare accessibility
I n J u l . 2 0 2 5 , t h e " M e d i c a l L a b o ra t o r y Q u a l i t y in underdeveloped regions such as Africa and contributing to global health equity and accessibility.
Management Training Course and ISO 15189 Internal
Auditor Training Course" hosted by the Guangdong
Association of Chinese Integrative Medicine was held
at the company headquarters to help promote the
standardized construction of the medical laboratory
quality management system, improve the laboratory's
quality management and technical capabilities,
and help medical institutions achieve high-quality
development.
International exchanges and cooperation >
In Dec. 2025, Snibe's representatives participated in a In Nov. 2025, during the China-Africa Medical Development
forum panel discussion at the WHX Leaders in Ghana. Forum held in Tunisia, the Tunisian Minister of Health visited
Strategic cooperation
Snibe's booth.
In 2025, we signed strategic cooperation memorandums with health departments of governments and authoritative
laboratory medicine associations in more than 20 countries around the world, and added partners in Latin America, Central
Asia, and Oceania. The types of signing institutions have also expanded from mainly professional associations to a wider
range of fields, such as governments, enterprises, universities, and international alliances. This move signifies the Company's
deepening cooperation and increasing influence in the international laboratory medicine field, and will help promote the
further dissemination and popularization of high-quality in vitro diagnostic products. Community Commonweal
Support for research and education >
Supporting scientific work
We actively fulfill our corporate social responsibilities by
contributing our fair share to promote inclusive diagnostic
knowledge, advance sustainable laboratory development,
cultivate diagnostic talent, and support education and medical
research. Supporting the development of
On Mar. 30, 2025, Hon. Kwabena Minitah Akandoh, Minister On Oct. 26, 2025, Dr. Raiva Simbi, Minister of Health of In 2025, the Company officially became an official sponsor public healthcare
of Health of Ghana, and Ms. Liu Haiyan, Deputy General Zimbabwe, and Ms. Liu Haiyan, Deputy General Manager of of the EFLM GREEN LABS program, deeply involved in and
Manager of Snibe, jointly signed a strategic cooperation Snibe, jointly signed a strategic cooperation memorandum supporting this important industry initiative that promotes
the sustainable development of clinical laboratories. Initiated In Oct. 2025, in order to promote the development
memorandum in Shenzhen. in Shenzhen.
by the EFLM "Green and Sustainable Labs Committee", this of public health and medical services and advance
program is dedicated to promoting the transformation of scientific research on laboratory medicine-related
Supporting clinical testing in countries of the Belt and Road Initiative laboratory medicine into a sustainable healthcare system. It programs, the Company donated RMB 500,000
Snibe actively responds to the "Belt and Road" initiative, vigorously advances business expansion in Africa, and is committed aims to make efficient use of resources from ecological, social, to the Zhong Nanshan Medical Foundation of
to strengthening China-Africa cooperation in the process of "going global" to achieve mutual benefit and win-win results. and economic dimensions, reduce energy consumption, water Guangdong Province.
waste, and the use of hazardous chemicals while ensuring
We actively participate in the China-Africa Health Cooperation Forum, working with health officials, medical institution the quality of medical services, and help Europe achieve its
representatives, and industry experts from various African countries to focus on the development path and future planning of carbon neutrality goal by 2050.
Industry Exchange and Cooperation Community Commonweal Industry Exchange and Cooperation Community Commonweal
We closely follow the outstanding young researchers and scientists emerging in the fields of clinical chemistry and laboratory
medicine. Through our continuous support of the IFCC Young Investigator Award and the IFCC Distinguished Award for
Laboratory Medicine and Patient Care, we recognize and encourage young scholars who have made outstanding scientific
achievements in the fields of clinical chemistry and laboratory medicine, as well as individuals who have made unique
contributions to improving patient care and generating global impact in the field of clinical medicine.
Sponsoring outstanding young researchers
On May 14, 2025, at the opening ceremony of Euromedlab in
Brussels, Snibe participated in and supported the IFCC Young
Investigator Award as a special sponsor of this important award. On Mar. 21, 2025, Snibe held a seminar on laboratory On Jun. 28, 2025, Snibe held a seminar on laboratory
The award aims to recognize young scholars under the age of medicine in Kenya. medicine in Ethiopia.
fields of clinical chemistry and laboratory medicine. This year's
laureate is Dr. Christopher Farnsworth. Ms. Liu Haiyan, Deputy
General Manager of Snibe, was invited to present awards to Supporting community commonweal >
the laureate, further showcasing Snibe's corporate image and
professional influence to industry experts and clients in Europe As a listed biopharmaceutical company with a strong sense of social responsibility and national commitment, the Company
and around the world. has always deeply integrated corporate social responsibility into its development strategy and proactively shouldered its
social responsibility mission.
Education is of paramount importance to both the country and the Party. Snibe attaches great importance to the high-quality
development of education and actively engages in science popularization and public welfare education, contributing to the
vigorous development of socialist education with practical actions. In 2025, the Company was awarded the title of "Science
Popularization Education Base" by the Science and Technology Innovation Bureau for its solid practice and outstanding
contributions in the field of science popularization education, which further consolidated the foundation of science
popularization education work. Upholding its commitment to social responsibility, the Company has carried out science
popularization and education activities. In 2025, it hosted teachers and students from Pingshan Foreign Language School
Empowering global diagnostics talents
and Shenzhen Pingshan Eastern Greater Bay Experimental School for visits and exchanges, totaling more than 60 visits. This
The Company is keenly aware of the importance of technical cooperation and has carried out a number of academic
provided students with a window to understand cutting-edge technologies and industry development in the field of medical
exchange activities in Africa in recent years, regularly inviting well-known lecturers to share their laboratory techniques
devices, effectively stimulating young people's interest and enthusiasm for scientific exploration and the biomedical field, and
and industry experience. These activities have enhanced the diagnostic and treatment capabilities of local medical staff,
fulfilling the Company's responsibility for science popularization and education.
promoted mutual learning and exchange of medical technologies, and strengthened in-depth interaction between the two
sides in their professional fields.
At the same time, in response to the national rural revitalization strategy, the Company has actively participated in rural
revitalization public welfare undertakings, donated RMB 10,000 to the Pingshan District Charity Association, and contributed
to rural development with practical donations, conveying corporate warmth and demonstrating the responsibility and
commitment of a national biopharmaceutical company.
On Apr. 24, 2025, Snibe co-hosted the Snibe Day On Mar. 14, 2025, Snibe held a seminar on laboratory
international academic lectures on laboratory medicine medicine in Tanzania.
with the International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC) in Algeria.
Key Performance Indicator Table Key Performance Indicator Table
Economic Indicators Water resource
Indicator Unit 2023 2024 2025 Indicator Unit 2023 2024 2025
Operating revenue 10,000 RMB 392,965.57 453,540.45 457,675.95 Water intake m3 235,533 244,266 250,223
Cost of operations 10,000 RMB 106,247.60 126,653.49 140,724.23 Water intake intensity m3/ 10,000 RMB 0.5994 0.5386 0.5467
Total Value of Assets 10,000 RMB 822,248.88 961,945.35 994,075.80 Volume of reject water recovered m3 19,396.80 20,870.10 21,679.70
Asset-liability ratio % 8.25 10.84 8.01
Waste
Net profit attributable to shareholders
of listed companies
Indicator Unit 2023 2024 2025
EPS RMB/share 2.1054 2.3271 2.0621 Biohazard waste Tons 95.50 149.3 122.32
Hazardous waste Tons 0.88 2.08 2.81
Environmental indicators General industrial solid waste Tons 51.60 87.00 211.46
Greenhouse Gas Emissions
Indicator Unit 2023 2024 2025 Environmental compliance
Direct emissions (Scope 1) Tons of CO2 equivalent 452.82 1,138.78 2,589.96 Indicator Unit 2023 2024 2025
Indirect emissions (Scope 2) Tons of CO2 equivalent 12,288.54 14,213.66 14,481.52 Total monetary value of significant fines RMB 0 0 0
Total emissions (Scope 1 and 2) Tons of CO2 equivalent 12,741.36 15,352.44 17,071.48 Total number of non-monetary sanctions Cases 0 0 0
Carbon emission intensity per unit Tons of CO2 equivalent/10,000 Cases brought through dispute settlement mechanisms Cases 0 0 0
of revenue RMB revenue
Energy source
Social indicators
Indicator Unit 2023 2024 2025
Purchased electric power kWh 21,735,492.00 26,480,307.55 27,281,049.87 Diversity and equal employment
Natural gas consumption m3 51,093.00 55,181.00 51,719.00 Indicator Unit 2023 2024 2025
Number of staff involved Persons 2,627 2,841 2,785
Diesel consumption Tons 12.60 12.09 9.89
Male employees % 64.94 63.57 63.38
Gasoline consumption Tons 27.30 27.33 25.16
Female employees % 35.06 36.43 36.62
Direct energy consumption Tons of standard coal 120.57 124.84 114.23
Male employees in management % 70.71 69.05 69.73
Indirect energy consumption Tons of standard coal 2,671.29 3,254.43 3,352.84
Female employees in management % 29.29 30.95 30.27
Total energy consumption Tons of standard coal 2,791.86 3,379.27 3,467.07
Employees under 30 years old % 62.31 62.44 58.42
Energy consumption intensity Tons of standard coal/ 10,000 RMB 0.0071 0.0075 0.0076
Key Performance Indicator Table Key Performance Indicator Table
Diversity and equal employment Occupational health and safety
Indicator Unit 2023 2024 2025 Indicator Unit 2023 2024 2025
Employees aged 30-40 years old % 33.80 33.09 35.73 Deaths and mortality rate of employee caused by work injury Persons;% 0 0 0
Employees aged 40-50 years old % 3.43 4.05 5.35 Occupational injuries excluding deaths and serious injuries Persons 5 6 7
Employees over 50 years old % 0.46 0.42 0.50 Losses of working hours due to occupational injuries Hours 635.04 1,773.04 1779
College degree or below % 29.62 27.49 26.71
Anti discrimination
Undergraduates % 52.87 52.76 52.42
Indicator Unit 2023 2024 2025
Postgraduates % 17.24 19.43 20.43
Total number of discrimination incidents during the reporting period Cases 0 0 0
PhD students % 0.27 0.32 0.43
Quality of product and service
Attraction and Retention of Employees
Indicator Unit 2023 2024 2025
Indicator Unit 2023 2024 2025
Quality management system certification Pcs 3 3 3
Number of new employees Persons 594 563 212
External regulatory review Times 5 6 5
Turnover Rate % 12.49 9.56 8.21
Third party quality system audit Times 7 8 8
Employee compensation and benefits Overall satisfaction with customer complaint handling % 100 100 100
Indicator Unit 2023 2024 2025 Events where fines or penalties are imposed for violations of regulations Cases 0 0 0
Employee labor contract signing rate % 100 100 100 Events subject to warnings due to violations of regulations Cases 0 0 0
Employee social insurance coverage rate % 100 100 100 Events that violated the voluntary code Cases 0 0 0
Events of Product recall quantity Pcs 0 0 0
Employee training and development
Indicator Unit 2023 2024 2025
Product R&D
Total training duration Hours 164,366 86,482 96,743
Indicator Unit 2023 2024 2025
Total number of trainees Times 33,109 13,298 33,899
Total number of R&D personnel Persons 693 836 781
R&D investment amount 10,000 RMB 36,604.71 45,358.80 47,776.93
Occupational health and safety
Cumulative number of patent applications Pcs 523 629 743
Indicator Unit 2023 2024 2025
Investment amount in environmental and occupational health & safety 10,000 RMB / 409.5 458 Valid patents granted Pcs 335 388 426
Coverage rate of occupational health examination % 100 100 100 Valid invention patents granted Pcs 142 169 197
Chemiluminescence immunoassay reagent projects provided globally Items 199 224 250
Key Performance Indicator Table Appendix
Supplier management
Issue Index of "Shenzhen Stock Exchange Self-Regulation Guidelines for Listed
Indicator Unit 2023 2024 2025
Companies No. 17 - Sustainable Development Report (Trial)"
Total number of new suppliers Suppliers 35 36 50
Number of suppliers disqualified due to quality issues Suppliers 0 4 4
Dimension No. Issue Section
Percentage of the Chinese Mainland suppliers % 95.21 95.90 96.30
Environment 1 Addressing Climate Change Addressing Climate Change
Marketing management
Indicator Unit 2023 2024 2025
Events where fines or penalties are imposed for violations of regulations Cases 0 0 0
Events subject to warnings due to violations of regulations Cases 0 0 0 5 Environmental compliance management Environmental and occupational health and safety management
Events that violated the voluntary code Cases 0 0 0 6 Energy utilization Addressing Climate Change
Customer privacy
Indicator Unit 2023 2024 2025
Society 9 Rural revitalization Community Commonweal
The total number of confirmed leaks, theft, or loss of customer information Cases 0 0 0
The total number of confirmed complaints received regarding violations of customer privacy Cases 0 0 0
Anti-corruption 12 Ethics of science and technology Focusing on R&D and Innovation
Indicator Unit 2023 2024 2024 13 Supply chain security Supply Chain Management
Number of anti-commercial bribery trainings Times 8 19 14 14 Equal treatment of SMEs Supply Chain Management,Responsible Marketing
Proportion of employees receiving anti-commercial bribery trainings % 100 100 100 15 Safety and quality of products and services Product Quality and Safety,Customer Service Quality
Proportion of employees signing anti-commercial bribery commitments % 100 100 100 16 Data security and customer privacy protection Compliance in Operation
and Development,Occupational Health and Safety
Governance 18 Due diligence Compliance in Operation
related to
sustainable 19 Communications with stakeholders ESG governance
development
Appendix Appendix
GRI Index Table
Indicator No. Indicator Name Report Chapter Indicator No. Indicator Name Report Chapter
GRI2：General Disclosures 2-27 Compliance with laws and regulations REGULATING CORPORATE GOVERNANCE,STRICTLY
CONTROLLING THE QUALITY OF PRODUCTS AND
SERVICES,TALENT EMPOWERMENT,PROMOTING GREEN
The organization and its reporting practices OPERATION,Appendix
Activities and workers 3-2 List of material topics ESG governance
Governance 201-1 Direct economic value generated and distributed Key Performance Indicator Table
Strategy, policies and practices GRI302：Energy
Appendix Appendix
Indicator No. Indicator Name Report Chapter Indicator No. Indicator Name Report Chapter
GRI303：Water and Effluents 403-3 Occupational health services Environmental and occupational health and safety
management, Occupational Health and Safety
management, Occupational Health and Safety
GRI305：Emissions management,Occupational Health and Safety
impacts directly linked by business relationships safety management
GRI306：Effluents and Waste 403-9 Work-related injuries Occupational Health and Safety,
Key Performance Indicator Table
GRI404：Training and Education
programs
GRI308：Supplier Environmental Assessment
Society 405-1 Diversity of governance bodies and employees Corporate governance, Attraction and Retention
of Talents, Key Performance Indicator Table
GRI401：Employment
GRI406：Non-discrimination
not provided to temporary or part-time employees
GRI416：Customer Health and Safety
GRI403：Occupational Health and Safety
management, Occupational Health and Safety
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Add: Snibe Building,No.23, Jinxiu East Road, Pingshan District, Shenzhen, P.R. China
Web: www.snibe.com
E-mail: snibeinfo@snibe.cn
Zip code: 518122
首页
微信公众号
证券之星APP
